[go: up one dir, main page]

WO2018145180A1 - Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject - Google Patents

Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject Download PDF

Info

Publication number
WO2018145180A1
WO2018145180A1 PCT/BR2018/000004 BR2018000004W WO2018145180A1 WO 2018145180 A1 WO2018145180 A1 WO 2018145180A1 BR 2018000004 W BR2018000004 W BR 2018000004W WO 2018145180 A1 WO2018145180 A1 WO 2018145180A1
Authority
WO
WIPO (PCT)
Prior art keywords
molecular patterns
antigenic agents
cells
agents
spp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2018/000004
Other languages
French (fr)
Inventor
Alexandre Eduardo NOWILL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,329 external-priority patent/US10213504B2/en
Priority to AU2018217441A priority Critical patent/AU2018217441B2/en
Priority to KR1020197026857A priority patent/KR20190139209A/en
Priority to JP2019564565A priority patent/JP2020507629A/en
Priority to MX2019009689A priority patent/MX2019009689A/en
Priority to CN201880023729.7A priority patent/CN110709099B/en
Application filed by Individual filed Critical Individual
Priority to EP18751350.2A priority patent/EP3579868A4/en
Priority to RU2019128674A priority patent/RU2019128674A/en
Priority to BR112019016670A priority patent/BR112019016670A2/en
Priority to IL268626A priority patent/IL268626B2/en
Publication of WO2018145180A1 publication Critical patent/WO2018145180A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of a immunological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (P AMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS) (I) and one or more physiological !y acceptable carriers, exeipients. diluents or solvents.
  • IRS immunological Response Shifter
  • P AMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • SRS Stress Response Signals
  • compositions of the present invention comprise immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or stress response signals (SRS) (1) selected from the group consisting of: (A) antigenic agents with molecular patterns associated with bacteria; (B) antigenic agents with molecular patterns associated with viruses; ( €) antigenic agents with molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; (E) antigenic agents with molecular patterns associated with multicellular parasites / or (f ) antigenic agents with molecular patterns associated with prions.
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • SRS stress response signals
  • the new "anti” chugs brought an enormous capacity for medical intervention, with numerous benefits, with definitive and partial cures, with the prolongation of life in incurable diseases, but also with huge morbidity due to side effects related to their lack of specificity to the pathophysiology of the diseases.
  • the irssaie immunity in addition to preventing the entry of microorganisms and preventing their establishment has another recently discovered vital function: discrimination between "self ! and "not self by the pattern recognition capability linked to the alarm and the command to start or inhibit an integrated immune response against an invading microorganism or to arrest, repair or inhibit a condition of destruction or self-aggression to the body, for example, in trauma, autoimmune diseases and allergic diseases, among others.
  • the recognition pattern of "not self, of an invasive germ is performed by sentinel cells, represented by epithelial cells, mucosal ceils, and the stromal cells, such as pericytes, dendritic cells, macrophages and fibroblasts, among others. These cells, strategically distributed throughout the body, have PRRs (Pattens Recognition Receptors) and DRRs (Danger
  • SRR stress response receptors
  • SRR stress response receptors
  • a) standard identification molecules, characteristic of a wide range of microorganisms b) certain patterns for chemical and physical of said inert substances and changes to metabolic stress, such as release of free radicals and tissue chemical changes., caused by ionizing radiation or by chemical substances, among others and c) stress receptor signals mat identify viruses, starvation, ER stress and oxidative stress (Pulendran, B Annual Review Immunology 2015).
  • the PR.R does not discriminate one specific individual microorganism, but the presence of microorganisms other than the human bom-'.
  • Each PRR receiver may bind to several different pathogens, recognizing as PAMPs (Pathogen Associated Molecular Patterns) carbohydrates, lipids, peptides and nucleic acids from bacteria, viruses, fungi or parasites that are not found in the human or animal body.
  • PAMPs Pulthogen Associated Molecular Patterns
  • the DRRs discriminate that, there is tissue damage, a dangerous situation caused by not live or inert agents.
  • the DRRs identify- DAMPs (Danger Associated Molecular Patterns) associated with tissue damage by toxic substances, radiation, or trauma, which cause metabolic stress, release of tree radicals and chemical changes in tissue, recognized by these receptors.
  • the SRRs stress response receptors identify' the signal of the metabolic stress caused by environment aggressions as viral infections or viral effective vaccines, amino acid starvation, ER(endoplasmic reticulum) stress, oxidative stress, through evolutionary conserved stress- sensing mechanism, that compose de integrated Stress Response ISR as recently discovered (Janeway C, Travers P. a!pon: M, SlMomchik Ml imtmmobioiogy five. 5th ed: Garland Pub.: 2001. 732 p.: Matzinger P. The danger model: a renewed sense of self. Science. 2002 ; 296 ( 5566) : 30.1 -5. Epub 2002/04/16; Beuiler BA. TLRs and innate immunity. Blood.
  • sentinel cells via their PRRs and their DRRs, and SRRs have a role in the breakdown of which belongs ("self) and which, is does not belong (not “self) and triggering inflammation and immune response, via recognition of PAMPs of invading pathogens and DAMPs caused by neoplastic ceils, inert substances and toxic substances or modifications due to trauma, or stress response signals in infections in ISR leading to a situation of real danger to the human and animal, organism .
  • NF-kB Nuclear Facior-kB
  • the innate immunity sentinel ceils with the APC role (Antigen Presenting Ceils), such as dendritic cells and macrophages, phagocytosis and pinocytosis microorganisms or tumour cells, or transplanted ceils, among other aggressors and process their antigens.
  • APC cells pulsed by the antigens migrate to regional lymph nodes and activate them.
  • the APC cells in reactive lymph nodes, activated and mature present the antigens to lymphocytes, release cytokines and thereby induce, coordinate, -polarize, amplify and maintain an adaptive immune response specific to the invading germs, or neoplastic ceils, or to transplanted cells, or other offending agent, allowing them to be fought and eliminated, where feasible and the consequent cure of the infection or inflammation and repair and regeneration or wound healing (1 ) (3).
  • APC function sentinels, and innate immunity effectors, cellular and molecular in conjunction with die cellular and molecular effectors of adaptive immunity that are respectively lymphocytes, cytokines and antibodies.
  • the interaction of the two immunities, innate and adapti ve, in the context of an infection, or immune response against an aggressor of any kind helps to fight the disease in an integrated and synergistic way.
  • the integration of the two initially occurs by the action of the innate immunity cells with APC function, such as dendritic cells and macrophages, but mainly by the activity- of dendritic cells, as they are the ones that are able to initiate an adapti ve immune response against a primary infectious or parasitic agent effectively protecting the body(2, 3).
  • APC function such as dendritic cells and macrophages
  • Macrophages also function as APC cells, but are more specialized and involved as part of the effector loop in phagocytosis and in the elimination of microorganisms.
  • B lymphocytes when mature, are also APC ceils and its most well-known action is the presentation of antigens to the T lymphocytes, within the framework of cooperation of bom lymphocytes to produce antibodies against T-dependent antigen, and the secondary antibody response in lymph nodes and bonne marrow.
  • Macrophages like other myeloid cells, are also involved in suppressing immune response in mostly in chronic infections or in acute infections, in these case of chronic infections or tumours, its performance is unfavourable to the defence of the organism because it suppresses the immune response and create a chronic infection or tumour facilitation.
  • the CD 40L molecule of activated T lymphocytes when it binds to the CD40 molecule on the APC ceils, significantly increases the expression ofCDSO and CD86 molecules, increasing the current response, which thus occurs only when the adaptive T response is already engaged in defending the body.
  • the third signal given by cytokines such as IL-j is given usually by the APC cells after the binding of co-stimulatory molecules and the emission of the second signal.
  • the JL-1 released by the APC ceils acts on lymphocyte ceils and leads to the complete expression of the receptor for 1L2 and to the production of 1.L2 and others polarization cytokines by virgin or memory 7 lymphocytes engaged in response initiating clonal selection and expansion(primary) or memory clonal proliferation (secondary).
  • the activation of innate immunity by pathogens or by aggression is the key to unleashing the second and third signals and the occurrence of a potentially effective immunity, through the full activation of T lymphocytes engaged in the response. Without the occurrence of the second and third, signal, the response is aborted and generates a tolerance specific to the antigen presented.
  • neutrophils, monocytes and macrophages initiate combat to bacteria and to other infectious agents by the linkage ofPAMPs with PRRs SRSs on antigen presenting ceils (APC), they activate dendritic cells and macrophages, local and newly arrived or best activated by memory cells. These cells phagocytosis and pinocytosis bacteria and bacterial antigens, processing them and starting the maturation process. The activated and maturing dendritic cells now migrate to regional lymph nodes to present antigens and initiate immune response against the invading agent.
  • effector memory CD4-CD40- L+cell migrate in a €D62P-dependent fashion into the reactive lymph nodes via H ' EVs and license dendritic cells for T cell priming against weak antigen, tolerate antigens and auto antigen starting an auto immune disease or improving an immune response in an ongoing infection or neoplastic disease(4).
  • effector memory CD8 T cells secrete CCL3, that in turn activate MFCs to produce TNF alfa that induce PMNNs and Others MFCs to produce ROIs and clear intracellular bacteria. Unrelated intracellular pathogen sensitive to ROIs can. also be clear by bystander activation in overlapping diseases or overlapping immune responses (6, 7).
  • isnmxmoglobulins collaborate with T helper cells, cells after contact with these antigens. proliferate, mature, and differentiate into plasma cells that now release specific antibodies against this bacterium in a first moment outside of follicular node in the B cell area, in activated lymph nodes and after differentiation goes inside and induce germinal centre fonnation and secondary B cells responses with collaboration with €D4Tfh and others CD4T helpers cells.
  • secondary B ceils responses long lived plasma cells secrete Tcell dependent antibodies in bonne marrow, after initial production in lymph nodes (1,6) (8, 9).
  • Infections of ail types, bacterial, viral, fungal and parasitic may, in general, in the acute phase, evolve to a full cure with regeneration and healing, or for a cure with sequelae. They can also develop into an incurable ciifonicity, with or without control of the disease, to chronicity with healing, with or without sequelae, or to death.
  • Treg/Td profile which suppresses the immune response aad controls, by inhibiting the other three profiles described above, ensuring the return of the body equilibrium state.
  • New profiles have been stablished, as the Tfh ⁇ follicular Helper) of the humoral response (16), the Th9 profile for certain parasites like Helminths ( 17),Th22 that produce IL22 involved in Skin protection ( 17) or other profiles that may be discovered or no fully estab!ished( 18).
  • the various profiles ensure the defence of the organism and the elimination of causative heterologous (infectious) agents invading and colonizing autologous (neoplasia).
  • the last classic profile ensures the termination of the immune response, die balance, the regeneration, the safe return to normalcy and it prevents self-injury and allergy and is therefore vital to -the health and preservation of the human species and animal, as much as the other profiles.
  • the phenomenon of polarization of the immune response is defined as the predominance of a certain, immunological profile such as Thl or Th2 at the expense of other profiles thai become secondary or null.
  • This phenomenon happens according to the type of attack suffered by the body. That is, according to die type of infection, pathology, and. infection stage or pathology stage, the different type of immune response will be predominant, and it may be a cellular, humoral, tissue inflammatory, or immune-regulatory response, while other types of immune responses are inhibited, resulting in the phenomenon of polarizat-on. ⁇ !2)
  • tuberculosis is the appearance of Thi7 ceils in the lung which allows Thl ceils to settle and may lead to cute this infection in the lung parenchyma (Siockmger, B. and Veidhoen, M. Differentiation and function of Thl 7 T cells. Current Opinion in Immunology, 19 (3), pp. 281-286. 2007).
  • the CTL cells ofThi profile destroy cells infected by viruses, to eliminate the vims.
  • antibodies are required to prevent the virus from infecting other healthy cells and thus preventing the spread of infection.
  • Dendritic ceils in collaboration with other APC and sentinel ceils is contact wi th different aggressors in different functional states, in the inflammation sites, in the lymph nodes, in the spleen, in the mucous membranes, are able to lead, coordinate, polarize, and amplify the adaptive immune response governing them, primary and secondary, e.g., specific, for the peptides of invading pathogens, which in this case is the most appropriate for the removal of the ongoing rafeetkm( 1 ,2,3)
  • dendritic cells and other APC cells are key cells of the innate immune response, since they evaluate the nature of the autologous and heterologous causative agent, i.e., the type of pathogen or colonizing cells and aided by the sentinel cells, tfeey measure and evaluate the size of the heterologous or autologous aggression, its extension, its intensity and aggressiveness, besides commanding the adaptive response with the profile and the intensity required for the elimination of the pathogen.
  • innate immunity comexiuaiize the aggression in a primary response and recontextualize in a secondary effective one by the action of T B and some NK memory cells (19) (20) (8, 9, 20-31)
  • a re-differentiation can occur, induced by the microenvixonment and/or the type of antigen or its presentation, in which a Thl or Th2 profile can be exchanged for an inflammatory profile or an immunosuppressant profile or vice versa.
  • This extreme plasticity of the immune system to differentiate or re- differentiate in either direction indicates a strategic window for manipulation of the immune system, during infection, when the direction taken by the polarization is not the best one for curing the infection process or neoplasia (32).
  • Thl? a profile, which in turn increases the inflammation more and therefore becomes detrimental, leading to tissue destruction, rather than inducing healing and paradoxically inducing late immunosuppression by the Treg/Trl profile and exhaustion state .
  • Thl7 profile by tissue destruction and the amplification of inflammation, is implicated in the generation of clinical complications such as severe ARDS (acute respiratory distress syndrome in adults), lung shock, renal failure, or shock, that compromises healing (4, 33, 34).
  • the same antibiotic is responsible for the clearance of this pathogen or responsible for the cure of the infection in vivo when its occurs.
  • the only conclusion that can be made in that case is: the success of the antimicrobial treatment in the clearance of the pathogen and in the cure of infection in vivo depends on the joint action of the antimicrobial drug and the immune system. in strong support of this view, the immune system is deficient in the extreme of ages, dysfunctional in elders and immature in the first years of age. In this periods of life, infections are usually more severe and frequent, and mere are also a higher rate of morbidity and mortality, even when antibiotics are used in correct indication, dosing and timing.
  • the inventors propose a new concept, in which the antimicrobial drags can be considered as equilibrium shifters (ES) in a host x pathogen competition, that favours the host immune system in a multivariable context.
  • the variables are: concomitant diseases, traumas, age, sex, race, psychological health, innate and adaptive immunity, metabolism, nutrition, physiological flora microbiota, environmental aggression by drugs, and exposure to radiation, gases, pathogens and medical treatments.
  • antimicrobial drugs by their action against bacteria facilitate the work of the immune system in pathogen clearance, reverting the host x pathogen equilibrium competition and promoting the cure.
  • the antimicrobial drags would function as equilibrium shifters of the host x pathogen competition by significantly: weakening the pathogens action and reducing their numbers is vivo and by that way facilitating the role of the immune system in microbe clearance.
  • Alternative outcomes are death or chronic infection, regardless of the use of antimicrobial drags.
  • one of the objectives of the invention is providing products comprising immunogenic compositions, in certain embodiments such compositions are combined wife one or more antibiotics, as well as methods and uses thereof for treating and/or preventing infectious diseases and preparing medicaments therefor.
  • It is a specific object of the present invention to provide immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of two or more Immunological Response Shifter (IRS) comprising an immune active antigenic agents that present pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS), and stress response signais(l) and one or more physiologically acceptable carriers, excipienis, diluents or solvents.
  • IRS Immunological Response Shifter
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • stress response signais(l) one or more physiologically acceptable carriers, excipienis, diluents or solvents.
  • immunogenic compositions for modulating the immune system which comprise immunological Response Shifters (IRS) that have immune-active pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or stress response signals (SRS) selected from the group consisting of: A) antigenic agents with molecular patterns associated with, bacteria; (B) antigenic agents with molecular patterns associated with viruses; (C) antigenic agents wife molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; ⁇ £ ⁇ antigenic agents with molecular patterns associated with multicellular parasites / or (F) antigenic agents with molecular patterns associated with prions.
  • IRS immunological Response Shifters
  • PAMPS immune-active pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • SRS stress response signals
  • the present invention also aims to provide uses of the above-mentioned immunogenic compositions for preparing pharmaceutical products and. methods for modulating the immune system., particularly for real-time replacement of an innefeciive immune response with an effective immune response.
  • the present invention aims to provide products and methods for treating infectious diseases, including severe infection, sepis and mufti rresistant bacteria, and modulating the immune system.
  • the effectiveness of the invention is due to a real time replacement of an ineffective immune response with an effective immune response. Such replacement made by proactively creating a new image of the aggressor pathogen to the host immune system, in order to reset lead back, control and improve the same.
  • an aggressive wiidtype virus would affect the host-pathogen balance in a different way than a vaccine virus, leading to a severe disease in one case and a subclinical disease in the other(l) (44-50).
  • an overlapping acute infection over a chronic one such as cancer or chronic infection, can induce the cure of the underlying disease (42, 51).
  • a strong activation can prevail over an ineffective one, improving the last one an altering the host x pathogen equilibrium competition and the outcome ⁇ 42,51).
  • the activation induced by the overlapping of an effective unrelated specific immune response is the best way known to rescue a state of tolerance, immunosuppression or anergy to a state of normal response (52)
  • Effector Memory CD8 T cells release CCL3, that in turn activate MFCs to produce TNF alfa that induce PMNNs and Others MFCs to produce ROIs and clear bacteria. Unrelated pathogen sensitive to ROIs can also be clear by bystander activation ⁇ 56-59). Recently, it was also recognized that the status of the rrucrobiome of the intestinal flora intervenes and can determine the effectiveness of a given vaccination.
  • the innate response is not specific by its own nature and can hold multiple specific adaptive responses at the same time and in the same territories with synergic or antagonist effects. Because human and animal organisms can bold multiple aggressions at the same time and even in the same territory, the sinks of the innate immunity receptors recognition system recognize an expandable and changeable universe of PAMPs, DAMPs, and Stress Signals in contrast to a defined recognition of the identity of an aggressor pathogen by adaptive immunity.
  • 5- lite major role of the primary response is to circumscribe the pathogen in a proinflammatory environment until an effective adaptive response takes place.
  • the primary adaptive response in acute infection is also proinflammatory. Both can be very harmful if the contact surface is big and usually induce a symptomatic illness and can also induce a deleterious lethal systemic inflammation
  • the secondary' innate and adaptive effective responses are provided by T, B memory cells and in some circumstances by NK memory cells that give a faster, correctly polarized, more accurate, quiet, low inflammatory and protective immune response, when available.
  • These modified secondary adaptive immune responses for its anti-infiammatory nature had to the ceils memory can effectively deal with systemic wide range of pathogen surface contact without being harmful for the human, and animal organism.
  • these effects can be obtained by the injections of a mix of FAMFs and secondary antigens to cognate memory cells that induce a secondary immune response and activate optimally PMCs and PMNNs to clearance bacteria, sensitive to, ROIs and other mechanism and activate optimally lymph nodes and improve ongoing immune response or can induce a poor or tolerated or no immunogenic one.
  • the immune system is reactive and not proactive and the quality and effectiveness of the natural immune response depends mainly of two factors;
  • First factor is the existence or not of an immunological effective specific memory that it determines a secondary or a primary immune response.
  • a secondary response the best possible response is available and the outcome is a quiet protection.
  • the new immune response is always circumstantially a. fortuitous reply and the outcome depends on the second factor and can be improved.
  • the second factor is the host x parasite competition balance (40, 49, 53, 54, 60-78) .
  • the immune system cannot improve by itself an already ongoing primary immune response and the answer for the question of how to change and improve an established initial primary improper immune response is apparently complex but strategically simple because there are only two factors determining the outcome of an immune response, in a primary immunological reply, there are only one remainder factor that is the context of the host x pathogen competition balance to be modified to possible improve the ongoing inefficient immune response.
  • the antimicrobial di'ags acts by weakening, the pathogens action and reducing their numbers in vivo, and would function as ES of the host x pathogen competition like describe and proposal above. By this action the antimicrobial drug alter positively the host pathogen equilibrium balance and the outcome but don't alter the nature of the ongoing primary response.
  • the strict reactive characteristic of the immune system in a primary response that depend mainly on the pathogen immnnogenieity and action, and on the fitness of the immune system, open the door for a proactive medical immune intervention that can use all the remainder vast immune potential of available reply to change the host x parasite competition balance in favour of the host with anew secondary standard of this initial IR.
  • This strategical and planned immunological action must be able to reset, lead back, control, modify and improve in real time the immune system action to induce a favourable secondary specific effective IR for positively alter the context of host x parasite competition and the outcome.
  • This new perceived identity may be built in all disease's lymphoid sites or not, or even inflammatory territories, in controlled periods, that naturally will change completely the activation by a secondary huge one.
  • the immune system could reprogram the immune response based mostly in secondary well known antigenic determinants with a minority of primary determinants deriving from the aggressive pathogen that will generate a complete new different effective specific and well polarized iimiume response. The best possible one will, be generated with secondary tracts in the secondary resetting, low inflanunatory territories.
  • This new IRS for the proactive action of the proposed and planed immunotherapy must be constituted by a. vast and very diverse pathogen secondary antigen universe for which the organism disposes an effective memory repertoire. These antigens must be with priority inert and be applied in all the territory of the illness exceeding its limits.
  • Such antigens should be able to induce a multiple huge secondary anti- inflammatory activation to overlapping completely the primary pro inflammatory activation induced by the pathogen. These antigens should be applied each 3 to 5 days, to inhibit the immune suppressive cells generation imitating a draw out illness.
  • the propose of this immunotherapy is to create at the biological level im new virtual but real exogenous ore endogenous pathogens full identified by the innate and adaptive immunity in his most part as a secondary and well know aggressor by memory effective ceils that will induce the best available immune response replacing the initial one. Changing the inner image of the pathogen picked-up by innate and adaptive memory cells we proactively change the context of the host x pathogen competition now in favour of the host.
  • the reactive immune system activated excellently by the proactive immunotherapy will real rime reprogram. reset and leads back the best available secondary anti-inSammators' specific immune response against the etioiogic agent reverting his initial advantage in an ongoing illness.
  • Another object of the invention is the use of immunogenic compositions for preventing and/or treating infectious diseases. Particularly, providing methods of treating bacterial infections arid sepsis and uses of the above-mentioned immunogenic compositions for preparing medicaments and kits for treating bacterial infections.
  • ⁇ 8CG refers to attenuated Mycobacterium bo vis. Bacille Calmette-Guerin;
  • D AMPS refers to danger associated molecular patterns
  • ⁇ DECA refers to the IRS composition la described in Example 1 of the present patent application.
  • ⁇ GM.-CSF refers to "Granulocyte macrophage colony-stimulating factor"; * PAMFS refers to pathogen-associated molecular patterns. • PFXJ: plaque forming units.
  • PPD refers to purified protein derivative of M. tuberculosis
  • ⁇ PPD refers to the fraction of the purified protein extract culture of Koch's bacillus ("Purified Protein Derivative").
  • the PPD is the major antigen of Mycobacterium tuberculosis;
  • ⁇ TDCI50 is a unit for quantification of viral particles and is the infectious dose in 50% of ceils in a tissue culture:
  • Koch's Tuberculin refers to inactivated Mycobacterium bovis iysate
  • Lf or "Limes flocculation units” is the international unit for quantifying antigens in toxoid, vaccines accepted by the World Health Organization;
  • the invention refers to a pharmaceutical product comprising one or more antibiotics with one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3, 4. 5. 6, 7, 8, 9, 10, 1 1 , 1.2, 13. 14, 15, 16, 17, 18, 19, or 20 or more) synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria. (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeasts.
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • Such pharmaceutical product may be a composition, a kit, a medical device or any other product which aims to deliver the antibiotics and the one or more immunogenic compositions as described above to a tissue.
  • the one or more antibiotics comprised in the pharmaceutical product of the invention may be selected from the following classes: Amino Acid Derivatives, Aminoglycosides, Aureolic Acids, Aziridioes, Ansamycias, Benzenoids, Carbapenems, Cephalosporins, Coumarin- glyeosides, Diphenyl Ether Derivatives, Epipolvlhiodioxopiperazines, Fatty Acid Derivatives, Glucosamine, Glycopeptides, imidazoles, indol Derivatives, Lipopeptides Macrolactams, MacToHdes, Nucleosides.
  • Penicillins and Cephalosporins (beta-Lactams), Peptides, Peptidyl Nucleosides, Phenico!es, Polyenes, Polyethers, Pyridines and Pyrimidines, Quinolones and Fluoroquinolones, Statins, Steroids, Sulfonamides, Taxoides and Tetracyclines.
  • the immunogenic compositions of the present invention comprise immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from the group consisting of: (A) antigenic agents with molecular patterns associated with bacteria; (B) antigenic agents with molecular patterns associated with viruses; (C) antigenic agents with molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; (E) antigenic agents with molecular patterns associated with multicellular parasites / or (F) antigenic agents with molecular patterns associated with prions.
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • the immunogenic compositions of this invention include pathogen- associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from among at least three categories (A), (B), (C), (D ), (E) and (F) described above.
  • PAMPS pathogen- associated molecular patterns
  • DAMPS danger associated molecular patterns
  • the immunogenic compositions of this invention include pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from among at least four categories (A), (B), (C), (D), (E) and (F) described above.
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • Antigenic agents of the present invention can be selected from epitopes, genetic materials, lipids, polysaccharides and/or immune active proteins of the present invention can be obtained by purification .from isolated fragments of material existing in nature or fractions denved from plant, animal or microbiological extracts, or produced by genetic recombination, preferably- derived from viral, fungal, parasitic or bacterial prion strains.
  • the antigenic agents of the present invention with molecular patterns associated with bacteria of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with bacteria of the genera Staphylococcus, Streptococcus, Enterococcus, Coiynebacterium, Bacillus, Listeria, Clostridium, Mycobacterium, Actinomyces, Nocardia, Eschericliia, Proteus, Klebsiella, Serratia, Enterobacter, Salmonella, Shigella, Pseudomonas, Burkholderia, Stenotrophomonas, Aemetobacter. Vibrio, Campylobacter, Helicobacter, Bacteroides, Neisseria, Moraxella, Haemophilus, Bordetei!a, Brucella,
  • Antigenic agents with molecular patterns associated with, virus of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with virus families Adenoviridae, Aienaviridae, Bunyaviridae, Coronaviridae, Fiioviridae, Flaviviridae, Hepadrtaviridae, Deitavims., Caiiciviridae, Herpesviridae, Orthom>3 ⁇ 4oviridae, Papovaviridae, Paramyxoviridae, Parvoviridae, Pjcomaviridae, Poxyvindae, Reoviridae, Retroviridae, Rnabdoviridae and Togaviridae.
  • Antigenic agents with molecular patterns associated with fungi and yeasts of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with fungi and yeasts of the genus Sporothrix, Aspergillus, Blastomyces, Candida, Coocidioides, Cryptococcus. Histoplasma and Pneumocystis.
  • An tigenic agents with molecular patterns associated with protozoa of the present invention may ⁇ be selected from, but not limited to antigenic agents with molecular patterns associated with protozoa of the genera Cryptosporidium, Cfcioapora, Entamoeba, Naegieria, Giardia,
  • Antigenic agents with molecular patterns associated with multicellular parasites of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with multicellular parasites trematodes. cestodes and nematodes.
  • the antigenic agents of the present invention comprise protein, polysaccharide, lipid molecules and/or composite syniJietic molecules that mimic protein, polysaccharide and/or lipid molecules.
  • the agents of the invention comprise immune-active antigenic protein molecules which have enzyme activity, for example kinases, phosphatases, streptoquinases, estreptodornases and Deoxyribonucl eases (e.g. domases).
  • enzyme activity for example kinases, phosphatases, streptoquinases, estreptodornases and Deoxyribonucl eases (e.g. domases).
  • the immunogenic compositions for modulating the immune sy stem of the present invention comprise from 0.001 to 500 micrograms per ml of each immunogenic agent.
  • Such immunogenic agents can be encapsulated in capsules, micro particles, narroparticles, coated tablets, liposomes.
  • the immunogenic compositions for modulating the immune system of the present invention comprise frorn 4 to 20 antigenic agents selected from the group consisting of antigens derived from agents: doraase, !evedunn, oidiomycin. PP.D, prions, strepioquinase,
  • Streptococcus toxoid diphtheria toxoid. Tetanus toxoid, Koch's tuberculin, inactivated lysate of Ascaris lumbricoides, Aspergillus spp., Aspergillus fiavus, Aspergillus fumigatus, Aspergillus ierreus, Caadida spp., Candida albicans, Candida glabrata, Candida parapsilosis. Chlamydia spp.. Chlamydia pneumoniae, Chlamydia psiitaci.
  • Chlamydia trachomatis Chlamydia trachomatis, Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius vermicularis, Enterococcus faecalis, Epidermophyton floccosum, Escherichia eolL Giardia lamblia, Haemophilus iafhienzae, Microsporum cannis, Mycobacterium spp.. . Mycobacterium bovis, Mycobacterium leprae.
  • Mycobacterium tuberculosis Neisseria gonorrhoeae, human papilloma virus. Polio virus, Proteus spp., Proteus mirabilis, Proteus penerii, Proteus vulgaris. Salmonella, spp. , Salmonella bongori. Salmonella enterica, Serratia spp. , Serraiia !iquefaciens, Serratia maxcencens. Shigella spp. Shigella flexneri. Shigella sonnei, Staphylococcus spp. , Staphylococcus aureus.
  • Staphylococcus epidermidis Sirongyloides stercorals.
  • Streptococcus spp. Streptococcus bovis.
  • Streptococcus viridans Streptococcus equinus, Streptococcus pneumoniae, Streptococcus pyogenes.
  • Toxoplasma gondii Trichomonas vaginalis, trichophyton, Trichophyton spp. , Trichophyton rubram. Trichophyton tonsurans.
  • Trichophyton mentagrophytes yellow fever virus, hepatitis B vims, rubella virus, varicella zoster vims, variola vims, mumps virus, measles vims, herpes vims and vaccinia virus or synthetic analogues that present pathogen-associated molecular patterns (PAMPS) and/or danger-associated molecular patterns (DAMPS) associated with these antigenic agents.
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger-associated molecular patterns
  • the immunogenic compositions for modulating the immune system of the present invention comprise 4, 5, 6, 7, 8, 9, 10, 1 L 32, 13, 14, 15, 16, 17, 18, 19, or 20 antigenic agents selected from the group consisting of antigens derived from agents: domase, ievedurin, oidioxnycin, ?PD, prions, streptoqsiinase.
  • Streptococcus toxoid diphtheria toxoid, Tetanus toxoid, Koch's tuberculin, inactivated lysate of Ascaris !umbricoides, Aspergillus spp., Aspergillus f!avus, Aspergillus fumigatus, Aspergillus terreus, Candida spp., Candida albicans, Candida glabrata, Candida parapsilosis, Chlamydia spp.. Chlamydia pneumoniae.
  • Chlamydia psittaei Chlamydia trachomatis, Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius verraicularis, Enterococcus faecalis, Epidermophyton fiocccsum, Escherichia coli, Giardia lambiia, Haemophilus influenzae, Mierosporum cannis, Mycobacterium spp.,
  • Mycobacterium bovis Mycobacterium leprae, Mycobacterium tuberculosis., Neisseria gonorrhoeae, human papilloma virus. Polio vims. Proteus spp., Proteus mitahiiis, Proteus penerii, Proteus vulgaris. Salmonella spp. , Salmonella bongori, Salmonella enterica, Serratia spp. , Seixatia liqwefaciens, Serratia marceacens, Shigella, spp. Shigella flexneri. Shigella sonnei. Staphylococcus spp. , Staphylococcus aureus.
  • Staphylococcus epidermidis Sirongyloides stercoralis, Streptococcus spp., Streptococcus bovis, Streptococcus viridans, Streptococcus equinus., Streptococcus pneumoniae. Streptococcus pyogenes. Toxoplasma gondii, Trichomonas vaginalis, trichophyton. Trichophyton, spp.
  • a preferred immunogenic composition of the invention comprises inactivated Mycobacterium bovis Iysate, purified protein derivative of M.
  • tuberculosis inactivated Staphylococcus aureus iysate, inactivated Staphylococcus epidermidis Iysate, inactivated Steptococcus pyogenes Iysate, inactivated Streptococcus pneumonia iysate, inactivated Enterococcus faecaiis iysate.
  • a preferred immunogenic composition of the invention comprising from. 0.001 to 1 ng/ml of inactivated Mycobacterium bovis Iysate, 0.00! to 1 ng/ml of purified protein derivative of M. tuberculosis, 0.1 to 300 ug/ml of inactivated Staphylococcus aureus Iysate, O. i to 100 ug/ml of inactivated Staphylococcus epidermidis Iysate; O. i to 100 ug/ral of inactivated Steptococcus pyogenes Iysate; 0.1 to 100 pg/ml of inactivated Streptococcus pneumonia Iysate; 0.1 to 100 ug/m!
  • inactivated Enterococcus faecaiis Iysate 0.01 to 10 ug/ml of streptokinase, 0.01 to .10 ⁇ / ⁇ 1 of doroase; 0.1 to 100 ⁇ / ⁇ of inactivated Candida albicans iysate; 0.1 to 100 ug/ml of inactivated Candida glabrata Iysate.
  • compositions of the present invention can further comprise excipients, such as bactericides, bacteriostats. antioxidants, preservatives, buffers, .stabilizers, pH adjusters, osmolality adjusters, antifoaming agents and surfactants, and residual antigen inactivating or fractionation agents, growth medium components and solvents commonly used in the production of vaccines and im monotherapies .
  • excipients such as bactericides, bacteriostats. antioxidants, preservatives, buffers, .stabilizers, pH adjusters, osmolality adjusters, antifoaming agents and surfactants, and residual antigen inactivating or fractionation agents, growth medium components and solvents commonly used in the production of vaccines and im monotherapies .
  • compositions of the present invention may be a solid, liquid or gel.
  • pharmaceutically acceptable carrier means a non-toxic solid, inert, semi-solid liquid excipieut diluent auxiliary- formulation of any type, or simply a sterile aqueous solution such as saline.
  • Some examples of materials which can serve as pharmaceutically acceptable earners are sugars such as lactose, glucose and sucrose, starches such, as com starch and potato starch , cellulose and its derivatives such as sodium caiboxy-methyl cellulose, a ethyl cellulose and cellulose acetate, cyclodextrin; oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil and soya bean oil, glycols such, as propylene glycol, polyols, such as glycerol, sorbitol, mannitol and polyethylene esters such as ethyl laurate, ethyl oleaie, agar, buffering agents such as aluminum hydroxide and magnesium hydroxide, alginic acid, pyrogen- free water, isotonic saline , Ringer's solution, buffer solutions of ethyl alcohol and phosphate as well as other non-toxic compatible substances used in.
  • compositions and vaccines described herein are available.
  • the particular selected mode will depend on the selected antigenic agents, the dosage required for therapeutic efficacy and patient to whom the composition is administered.
  • the methods of the present invention can generally be practiced using any mode of administration biologically acceptable, i.e.. any means that produces effective levels of immune response without causing clinically adverse reactions.
  • modes of administration include intradermal, oral, rectal, sublingual, topical, nasal, transdermal or parenteral administration.
  • parenteral includes subcutaneous, intravenous, epidural, irrigation, intramuscular, release pumps or infusion.
  • oral, intradermal, parenteral, subcutaneous, intravenous, intramuscular, and, by the nasal mucosa and/or oral administration are preferred for administration of the composi tions claimed herein.
  • the active Ingredients may also be dissolved in a pharmaceutical carrier and administered as a solution, emulsion, including micro-and naao-emulsions or suspension .
  • suitable carriers are water, saline, dextrose solutions, fructose solutions or Oils of animal, vegetable or synthetic origin.
  • Other vehicles may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like.
  • the invention refers to a method to treat sepsis in a human or an animal who has a bacterial infection comprising administering to the human or animal an effective amount of one or more antibiotics and one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, I I, 12, 13, 14, 15, .16, 17, 18, 19, or 20 or more) synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen- associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses, ( €) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with helminthes, and
  • PAMPS
  • Septicemia is defined as an extremely serious infection in which one or more bacteria or microorganisms, from their entry point, enter the bloodstream and start circulating in large numbers, getting established at distant points, colonizing tissues, organs, and in the most severe cases, can successively reach most of the body surface and causing sepsis as a generalized inflammation that compromise the circulators' system.
  • septicemia leads to sepsis, through the massive release of proinflammatory cytokines such as TNFs, ILL IL18, 1L6 and others, causing an inflammatory collapse with hemodynamic characteristic alterations, such as hypotension, rapid pulse, which may culminate in septic severe shock, usually irreversible.
  • Septicemia, sepsis are serious infections/inflammations with high morbidity and mortality. In these severe
  • the immune system in turn, with its compromised operability by weaknesses and blockages induced by bacteria., starts to act so as to eliminate the bacteria at any cost, through the cytokine storm and through the inflammatory Thl7 tissue profile, increasing inflammation disproportionately and therefore harming the organism (33).
  • the effector loops of innate immunity controlled by the TCD4 lymphocytes, cause tissue damage and sometimes massive destruction, that compromise organs and tissues and that exacerbate infections, leading, for example, to respiratory failure, lung shock, and in ARDS (adult respiratory distress syndrome), also leading to renal failure and multiple organ failure.
  • IF used the loop amplification by IL2 should be very low, just enough to specifically amplify the repolarization of the immune response of the inflammatory profile to the immunity profile or to Treg/TRI regulatory profile.
  • the recontextoalizing and the rsprogramming achieved by immunotherapy using the compositions of fee present invention to achieve a new perceived identity of the pathogen, by recovering immune cells through the anti1 ⁇ 2flammatory action of non-related specific memory T lymphocytes, by the inhibition of the cytokine stoma and also by the repolarization of the tissue inflammatory profile TH17 to elective and effective TH! and ⁇ 2 immunity profiles, will together redirect the immune response.
  • fee invention refers to a method to treat multi resistant bacteria infection in a human or an animal who has a bacterial infection comprising adnfensfering to the human or animal an effective amount of one or more antibiotics and one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3. 4, 5, 6, 7, 8.
  • PAMPS pathogen-associated molecular patterns
  • DAMPS danger associated molecular patterns
  • the invention refers to a method to modulate an immune system response in a human or an animal who has a bacterial infection comprising administering to the human or animal an effective amount of one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3 ; 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14.
  • PAMPS pathogen- associated, molecular patterns
  • DAMPS danger associated molecular patterns
  • the present invention refers to the use of immunogenic compositions in the manufacture of medicaments and kits for preventing and/or treating of infections diseases.
  • Immunogenic compositions of the invention are also may also be used in. the pre vention and/or treatment of infectious diseases in association with one or more antibiotics.
  • the immunogenic compositions of the present invention have an unexpected effect on the immune response.
  • the immunogenic compositions of the present invention show an unexpected technical effect of causing an immune response that. involves resecting , recontextualizing, leading back, renewing and reprograraming the immune response in real tuns.
  • the iniinurioiherapeuiic compositions of the present invention by creating a new identity of the pathogen perceived by innate and adaptive immunological system are capable of provoking a reset, a recontextualization a lead back of the operational action capacity of the immune system by changing the relationship offerees against the aggressors in its favor, giving the immune system a competitive advantage, which does not occur spontaneously in the evolution of disease.
  • This recontextuaiization determines a consequent, renewal and reprogramming of the established immune response or incipiently established, or erroneously established mistakenly attacking in a dysautonomical way the human or animal body, polarizing the primary pro-inflammatory response that is always a fortuitous reply possible to be improved to a secondary, active anti-inflammatory, more effective and appropriate immune response.
  • compositions of this invention properly reset the activated sentinel ceils, the activated dendritic cells and other activated APC cells, by the action of memory cells, generating a new degree and intensity of CD4 T cell with a secondary activation profile that turn to a secondary effective standard the degree and. intensity of the immune profile to properly treat the infection without causing immunological side-effects, such as inflammation.
  • the immunomodulatory antigenic compositions of the present invention when in larger or significant amounts completely change the perceived image of the pathogen and trigger a specific secondary active adaptive immune response, desired to treat bacterial, viral or parasitic infections with a low inflammatory profile.
  • the treatment with the immunogenic compositions of the present invention is capable of stunuJatmg the regenerative power of the immune system, a natural physiological property of this system providing a subsequent effect to the elimination of infectious disease and other diseases: to recover cells and tissues, by restoring organ function debilitated from trauma and damage which cause the loss of part of the organism.
  • This property was demonstrated in the clinical cases of irreversible sepsis reported is the Examples. The patients had recover ⁇ ' and regeneration of complex trauma wounds with important tissue loss, organ destruction in lungs, kidneys, liver, bones and extremities induced by CIVD, and ischemic events by low blood flow and toxicity.
  • the immunogenic compositions of the present invention are able to mobilize the immune system and lead to an increased regenerative power of fee body, through mobilization of stem cells or the activation of gene sets which allow the regeneration of ceils and tissues and can even reconstruct organs and their functions, and can reconstitute organic systems such as the vascular system, the nervous system and the endocrine system, among others.
  • the im munogenic compositions of the present invention exhibit an unexpected technical effect of recontextxaalizing, renewing, and reprogramming the immune response in real time and consequently significant cure rates when compared to drugs and methodologies in the art.
  • immuno-moduiator agent(s) is/are used for preparing an immunotherapy pharmaceutical composition capable of inducing a new innate secondary immune response, which triggers a cascade of immune events, including the main event of activation of memory lymphocytes from the ageni(s) inoculated by human intervention and the concomitant activation by antigens present in the patient's own body, resulting in a.
  • the administTation of the composition containing the agents of the present invention repolarizes or improves the polarization of the immune system in the presence of a disease when the established polarization is inadequate, by the action of the etiologic agent or colonizer.
  • the activities of the agents of the present invention affect the shape, time, accuracy and polarization of the immune response., preferably leading to an secondary innate and adaptive immune response that it is snore effective to fight the disease, leading to a better reaction of organism itself.
  • the present invention provides methods to -treat bacterial and other microbial infections with the use of the antigenic combinations described.
  • Hie present invention also provides for the possibility of adding traditional therapies to the agents of this invention, aiding the process of elimination of the etiological heterologous invading agents and of the colonizing autologous cells, through the real therapeutic potential of antimicrobial drugs, selective for the pathogens and other infectious agents. This is made possible by the principle of displacement of the biological equilibrium in favor of the patient in combination with a correct polarization of the immune response as described herein.
  • the continued activation of the immune system by antigens or immunomodulatory 1 agents of the present invention leads, through the activation of stem cells, to the regeneration of tissues, organs and systems, by mechanisms not yet fully understood, but related to healing or restitution ad integrum mechanisms observed in various medical situations.
  • compositions of the present invention allow the recruiting of the maximum number memory cells, new effective virgin cells of the individual, producing more significant effects than an antibody increase as described in the prior art.
  • the present invention unlike the prior art, applies a greater and diverse amount of bacterial components, having representatives of both intracellular and extracellular bacteria in the composition, besides components of viruses, parasites, fungi and yeasts.
  • the present invention encompasses more areas of the body and tissues that have sentinel aid APC cells, and preferably looks for exposure on locations close to the infection sites and other distal applications to the disease sites (as is the case in disorders or diseases that manifest themselves in specific locations of the body) to secondary reset innate system in all the places of the disease.
  • the compositions of the present invention when applied according to the process of using the present invention in one or, usually, at various strategic of body regions drained by lymphoid territories or primary and/or secondary lymphoid organs, or even intralesiona!, are perceived by the PRRs (pathogen-associated pattern recognition receptors) off all sentinel cells of the body.
  • the present invention employs immunomodulatory agents in amounts, concentrations and specific locations to recontextuaiize, reset and lead back the immune system, activating and redirecting the mechanisms for tissue repair and regeneration, as occurs during healing and regeneration of tissue, organ or system, leading to a "restitution ad integrum" or reconstitution with scar.
  • This repair is usually triggered at the end of an immune response process, after healing die infection.
  • the immunogenic compositions of the present invention constitutes another aspect of the present invention using the immunogenic compositions in the manufacture of medicaments for the prevention and/or treatment of infectious diseases.
  • infectious diseases can be of viral, bacterial, fungal or parasitic origin.
  • HIV hepatitis virus
  • herpes virus rhabdovirus
  • rubella vims smallpox virus
  • poxvirus poxvirus
  • Diseases of bacterial origin prevented and/or treated by the immunogenic compositions of the present invention may be caused by the following bacteria- hut not limited to, Pneumococcus, Staphylococcus., Bacillus, Streptococcus, Meningococcus, Gonococcus, Escherichia, Klebsiella. Proteus, Pseudomonas, Salmonella, Shigella. Haemophilus, Yersinia, Listeria,
  • Fungal diseases prevented and/or treated by the immunogenic compositions of th e present invention may be caused by the following fungi but not limited to: Candida, Aspergillus, Cryptococcus neofortnans, and/or fungi that cause superficial and deep mycosis.
  • Diseases caused by parasites are caused by the following parasites: Trypanosoma, Schistosoma-.
  • compositions of the present invention are administered once, sis one area of the body or in difierent sites in order to redirect the immune system with the highest possible efficiency.
  • immunogenic compositions of the present invention for modulation of the immune system, involving the exposure of part or all of the system for recognition of antigens in the immune system, such as dendritic cells, macrophages and lymph nodes from different parts of the body, inflammatory territories will depend on the goal imposed by fee illness being fought, and occurs preferentially through injections or use of guns, or delivery systems or controlled, mfusion or pulsed cells with in vitro antigens.
  • the agent may be applied to only one location in the body or in several tens of locations in several forms: subcutaneous, muscular, intravenous, oral, breathable aerosol, cutaneous (dermal, patches) in organs, the viscera, or specific tissues, or in different body cavities, which can vary in number from one to one hundred (100) applications in one to fifty (50) sessions.
  • the antigenic compositions of this invention may also be combined with other drugs feat can weaken the reproduction, growth, or any other form of strengthening of the disease's causative agent, causing a shift of "the equilibrium in favor of the biological immune defenses of the host, animal or human. Or still in concomitant treatment.
  • the antigenic compositions of this invention may also be combined wife other procedures such as. but not limited to, antibiotics chemotherapy, therapy with antibodies and antisera, using hormones or other physiology modulating agents (cytokines, chemokines , neurohormones, peptides), treatment with antiviral agents, use of herbal medicines, vitamin supplementation, methods of therapeutic or prophylactic vaccination (with or without cells and not limited to the type of vaccine vehicles), gene therapy, surgery or homeopathy, depending on the disease or illness being fought related to an improper or inefficient immune activity. Recenlextualszing, resetting, renewing, leading back and reprograssming the immum response.
  • hormones or other physiology modulating agents cytokines, chemokines , neurohormones, peptides
  • treatment with antiviral agents use of herbal medicines, vitamin supplementation, methods of therapeutic or prophylactic vaccination (with or without cells and not limited to the type of vaccine vehicles), gene therapy, surgery or homeopathy, depending on the disease or illness being fought related to an improper
  • Recontextua3iz3Bg and resetting the immune system is achieved by means of stimulation of the immune system by antigens of different pathogens not related to fee pathology to be treated, for which the human or animal, preferably, already has an immunological memory for totally changing the inner perceived primary image of the invader pathogen to a new secondary effective proactively induced one.
  • These stimuli m ast be capable of causing an intense, strong and effective secondary specific immune response to these antigens of the new identity at the site of application, in the regional activated lymph nodes, in the lymph nodes at a distance and a systemic mobilization of the immune system so that it can, in parallel cause an effective secondary response capable of eradicating the specific pathology in progress.
  • the innate and adaptive secondary nnmune response caused intentionally by the composition of the present invention should encompass the full extent of the body area affected by the condition being treated and even exceed it if possible to be able to activate the sentinel and APC cells in the number and intercity that would be needed to properly address the aggression caused by the pathogenic disease to be treated, and activating and triggering the best specific adaptive secondary response, effectively and property sequentially polarized, in order to cure the condition being treated.
  • the innate and adaptive response induced by the present invention will geographically overlap the condition being treated and by its intense and extensive secondary activation will correct the inefficient activation, picposely limited by the action of the pathogen that overcomes the body's defenses, by preventing competition, its proper mobilization and development of an effective adaptive response according to its greatest genetic and biological potential.
  • This ideal activation should also reverse the immunosuppression, the tolerance and escape mechanisms established by pathogens because it is known and proven ' that an unrelated strong and intense immune response, that fully covers the response to be corrected., through the activated cells and cytokines of the immune system, will correct these deficiency situations efficiently.
  • Effector cells and memories of specific antigens of the present invention activated and generated at the site of application of fee antigens, will, via the bloodstream, enter the already activated lymph nodes by HEVs, which drain the region affected by the disease and will enable, in a strong and intense way induce fee activation of ail the existing dendritic cells there.
  • lymph node capable of provoking an immune response against, weak antigens, which by themselves are not capable of causing an immune response.
  • PAMPs alone can remodel lymph node feed arteriole and induce lymph node hypertrophy that is essential for an effective primary adaptive response and also for secondary- immune responses
  • the areas of the inflammatory process and lymphatic territories are exactly the same.
  • the inflamed area through the anti-inflammatory action of specific memory ceils, unrelated. mobilized by the present invention by their antigenic composition, will block the
  • inflammasGmes and exert an anti-inflammatory action that will correct the pathological inflammation responsible for the morbidity of the disease and which was caused by its etiological agent.
  • this known action of the memory T cells is the major responsible for the fact that a second contact with any pathological agent, after an already established immunity, is asymptomatic, without causing a disease.
  • lymphatic territories are exactly the same, only sow intensely activated and with the necessary alarm signal caused by the present invention, to cause any immune response, even for a weak antigen, similar to what occurs with dendritic cells common to this invention and to the autologous or heterologous etiological agent to be fought. Lymphokmes and innate cells that command an effective secondary response will be the same and the T lymphocytes specific against the etiologic agent, to be fought, will "hitch a ride" on this ideal microenvironmeni for holding an effective immune response.
  • the dendritic ceils activated by the present invention can capture the antigens of the etiological agent to be fought at the site of the pathology and in the related lymphatic territories and be in contact with the pathogen specific TCD4 lymphocytes, in a correctly and ideally enabled lymphatic system.
  • the role of the dendritic cells activated and matured with fee TCD4 specific to the etiologic agent occurs in a microenvironment conducive to conducting an immune response, with all the genetic and biological potential of the host organism's immune system.
  • dendritic cells at the site of the pathology and at the lymph nodes will properly gauge the severity, extent, intensity and type of aggression, activating, inducing, coordinating, polarizing, leading and maintaining a new effective adaptive immune response., whose effector loop, with tiie collaboration of the cells and effector molecules of the intense and properly activated innate immunity may be able to eliminate the causative agent to be fought. So the answer is reprogrammed and lead back as noted above, reversing the biological balance in favor of the host, which until then was under the yoke of the offending autologous or heterologous agent.
  • Such action may occur with or without the help of biological balance shifters such as antibiotics drugs, capable to block, weaken or neutralize the effects and potential of the etiological agent, allowing the immune system to have a chance to heal the pathology that is the target of the treatment.
  • biological balance shifters such as antibiotics drugs, capable to block, weaken or neutralize the effects and potential of the etiological agent, allowing the immune system to have a chance to heal the pathology that is the target of the treatment.
  • compositions of the present invention intentionally and strategically superimposed over the entire area under the action of the agent to be fought, will recontextualize the immune system by activating the PAMPs and DAMFs in the sentinel cells and common APCs and by the unrelated specific secondary adaptive immune response.
  • This intentionally induced immune response will efficiently activate the whole lymphatic territory and the organic territory affected by the etiological agent, in the recontextualized area and in the bulge, and within the context of a greater immune response, stronger, more intense and more extensive secondary anti-inflammatory nature of the target immune response will be, as described, reprogrammed and efficiently renewed within the scope of a greater chance for the host, now with a chance of reversing the biological balance in its favor,
  • Be therapeutic protocol of the present, invention designed to be applied in cases of bacterial infection and septicemia must:
  • the immunotherapy formulation must contain at least 5 antigens so it contains PAMPs and DAMPs so as to be able to recontextuaiize the immune system.
  • the application area mast overlap, cover, and overcome the whole extension of regions dominated by the infection.
  • the antigenic stimuli must be repeated every 4 or 5 days in order to avoid the generation of suppressor cells capable of aborting the new desired immune response or to suppress an achieved repolarization.
  • the treatment must be maintained in Ms manner until the end of the infection, or to the healing of fee wound, organ or system.
  • the immunotherapy is "systemica!!y” distributed in several (at least ten) lymphatic territories, peri- and mtra-lesion with a volume able to disrupt and destabilize the lesion from the domination of its micro and macro environment or cover the area significantly affected by infection and inflammation, as well as to restore the microenvironment that is favorable to the immune response of the organism. It will be applied every 4 to 5 days.
  • Figure 1 shows images ofExamie 2.
  • a I , .A3 and A4 show wounds after surgical cleaning on January 29, 2011. It's possible to notice injury of polytrauma associated with sepsis caused by mu!ti -resistant strain and major tissue loss that continued to perform poorly with a winy general appearance without any appearance of healthy granulation tissue. It is possible identifying, in X- Ray on January 29, 2011 (A2) fee external fixation of the femur after surgical procedure. On February .2, 201 1 (5 days after starting the treatment) the patient presented complete recovery from sepsis and received ICU discharge (BL B2 and B3).
  • Figure 2 shows images of Example 3.
  • a Chest CT scan Al aad A2 of 01/1 1/201 i before muriunotherapy and CT scan (81 and B 2) of 04/1 1/201 1 after immune treatment performed in CMS patient, in Al and A2 is possible to identify whitish areas (circled) characteristic of infection.
  • BI and B2 is clear the disappearance of whitish areas and recovery of the !ung parenchyma which the image became darker.
  • Figure 3 shows images of Example 4.
  • An X ⁇ Ray (Al) of 24 April 2007 (3 days after immiuioiherapy starts ⁇ and CT scan (B I to B6) of 27 April 2007 it's easily to identify critical SARS condition under septic shock.
  • X-Ray (CI) of 06 May 2007 evidences complete recover after immune treatment performed in AMB patient.
  • a I is possible to identify whitish areas (circled) characteristic of infection.
  • B i - B6 the clinical status is so critical that whitish areas barely allow to identify anatomical contours our parameters (circular).
  • C I is clear die disappearance of whitish areas and complete recover ⁇ ' of the lung parenchyma, without sequels, which the image became darker.
  • compositions to meet the technical requirements for the advantageous or unpublished results in treat a number of diseases and illnesses, they must have a high diversity of antigens from pathogens, so as to get the maximum synergistic effect in binding the PAMPs and DAMPs to their receptors and allowing the achievement of a high degree of activation of the innate immunity in the sentinel ceils (with or without ATC function) thereby allowing the reeontextualizing, renewal and reprogrammiog of the immune response in real time.
  • compositions should preferably use antigenic agents for which most people, because of previous contact, would have memory clones of in their immune system capable of inducing a broad anti-irtflamraatory action in parallel to rscontexiuaikarion .
  • antigenic agents should preferably be selected that:
  • ⁇ correspond to the most common infections contracted by the individual from childhood to maturity (when the animal or die human being acquires its "repertoire of immuniiy").
  • ⁇ are used in immunization programs such, as childhood vaccination programs against, endemic and ' Or epidemic diseases.
  • each of the antigeni c agents should be present in a concentration of 0.001 to 500 micrograms per mL.
  • antigenic agents m their already available, safe, and approved forms for use in human vaccination programs or allergic response tests and immunity assessment tests.
  • composition la (DECA composition):
  • Composition 12 is a composition of Composition 12:
  • Composition 17 is a composition of Composition 17:
  • the formulations When there are parasitic diseases, associated or to be fought, the formulations will preferentially contain antigenic agens of parasitic origin.
  • the formulations should comprise antigenic agents originating from the most prevalent parasites for which the indi viduals have more- memory cells, according to the geographic distribution and the local and regional human development (developed or non- developed countries). Such parameters are determinant for the occurrence of these parasites and the existence of corresponding memory ceils in the immune system of the population of a given region.
  • Composition 37 Association of Composition 2 with:
  • Composition 44 Association of Composition 9 with:
  • Composition 50 Association of Composition 15 with: Inactivated Ascaris Iumbricoides iysate 400 .ug/mL j Inactivated Strongyloides stercoraiis Iysate j 400 pg/rnL
  • Composition 56 Association of Composition 21 with:
  • Composition 57 Association of Composition 22 with:
  • Composition 58 Association of Composition 23 with:
  • Composition 59 Association of Composition 24 with;
  • Composition 60 Association of Composition 25 with
  • Composition 65 Association of Composition 30 with:
  • compositions DECA were applied, 1.8 cc each, for infiltration of exposed raw areas.
  • the first phase of immunotherapy began on 29 January, 2011 and ended on 19 March. 2011 totalling a total of nine DECA applications in. periods ranging from one to two times per week, once the cleaning and debridement schedule was being followed, in the operating room (due to the severity of the pain and risk of infection by the broad extensive exposure of internal tissues in the raw areas).
  • Acinetobacter baunnamii sensitive only to polymyxin B.
  • the patient was discharged on .15 March, 201 1, with complete cure of the infection of all complex injuries and wounds, including osteomyelitis.
  • the patient was discharged without antibiotic therapy.
  • Example 3 Treating sepsis associated with urinary infections and concomitant oropharynx with terminal gastric carcinoma
  • hypoglobin 8.6 g/dL also had hypokalemic, hyponatremic and lyraphopenic (lymphocyte count of 3,000/microliter) condition.
  • the immunotherapy treatment was performed during a single session on 04 October. 201 ] with the informed consent of the patient.
  • VITER immunotherapy was performed as follows:
  • the immunostimu!ation caused immiasocompetence recovery and acti vation of the effector T loop as the lymphocyte count increased from 3,000/microliter on 03 October., 20.1 ito
  • the innnimostimulaiiori of the present invention allowed for as unexpected survival of I year and. a half, enjoying the company of relatives.
  • Example 4 Treating infection (mu!tireststant bacteria of SARS in septic shock)
  • SARS Severe Acute Respiratory Syndrome
  • ICU Intense Care Unit
  • Coagulation arid make opsonization, process possible, inspite of all efforts patient did not expcrince any clinical and laboratory improvement.
  • the immunotherapy treatment was performed nine sessions starting on 21/04/201 1 after informed consent of the patient.
  • DECA immunotherapy was performed as follows:
  • Streptokinase derived from lysate inactivated and purified Streptococcus beta-hemolytic 0,404 ug/mL); 6. Domase derived from lysate inactivated and purified Streptococcus beta-hemolytic 0, 10! pg/mL); 7. Gidiomycm (antigenic extract of Candida albicans 6,31 ⁇ g/mL); 8. Trichophytin (antigenic extract of Tricophyton spp 6,31 ⁇ / ⁇ ,); 9. Lysate inactivated Escherichia co!i (EP.EC 6,31 p.g/m.L); 10. Lysate inactivated Salmonella (Salmonella hongori, Salmonella enterica and Salmonella subierranea in equal parts 6,31 ,ug/mL).
  • Pulendran B The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annual review of immunology. 2015:33:563-606. 2. Steinman RM. Decisions about dendritic ceils: past, present, and fliture. Annual review of immunology. 2012;30: 1-22.
  • Soderberg KA Payne GW, Sato A, Medzhrtov R, Segal SS, Iwasaki A. Innate control of adaptive immunity via remodeling of lymph node feed arteriole. Proceedings of the National Academy of Sciences of the United States of America. 2005;102 ⁇ 45): 16315-20.
  • Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis. Shock.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention refers to pharmaceutical products comprising immunogenic compositions for modulating the immune system, which therapeutically effective amount of a Immmological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS) in association with an antibiotic and one or more physiologically acceptable carriers, excipients, diluents or solvents. In other embodiments, the present invention refers to methods to treat severe bacterial infections, sepsis and modulating the immune system.

Description

IMMUNOGENIC COMPOSITION FOR MODULATING THE IMMUNE SYSTEM AND METHODS TO TREAT BACTERIAL INFECTIONS IN A SUBJECT
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. Patent Application Serial No. 14/006,077 filed October 2.3, 2013, which, is the National Phase of International Application No.
PCT/BR2012/000072, filed March 19, 2012, which designated the United States, which also includes a. claim of priority under 35 U.S.C. §119(a) and §365(b) to Brazilian patent application No. PI 1100857-1 filed March 18, 2011, the entirety of all applications is hereby incorporated by reference.
FIELD OF THE INVENTION
The present invention relates to immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of a immunological Response Shifter (IRS) comprising two or more immunoactive antigenic agents presenting pathogen-associated molecular patterns (P AMPS) and/or danger associated molecular patterns (DAMPS) and/or Stress Response Signals (SRS) (I) and one or more physiological !y acceptable carriers, exeipients. diluents or solvents.
The compositions of the present invention comprise immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or stress response signals (SRS) (1) selected from the group consisting of: (A) antigenic agents with molecular patterns associated with bacteria; (B) antigenic agents with molecular patterns associated with viruses; (€) antigenic agents with molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; (E) antigenic agents with molecular patterns associated with multicellular parasites / or (f ) antigenic agents with molecular patterns associated with prions.
BACKGROUND OF THE INVENTION
From the pioneering discovery of antibiotics in the end of first half of the 20th century, new antibiotics, semi-synthetic antibiotics and new chemotherapeuiics with antimicrobial activity". have been developed on a large scale against roost intracellular and extracellular bacteria. These developments have changed the history of medicine, allowing it to reach a wide spectrum of healing, for the vast majority of bacterial infectious diseases, which racked humanity.
The discovery of antibiotics asd other drugs
Thus, the discovery of antibiotics was a major milestone, a watershed, because infection could be addressed arid healed, in a specific way, with a clear relationship of cause and effect and measurable when established. This disco ver}' greatly expanded the ability of healing in medicine, with enormous positive impact on human health and lifespans. The discover}' of anti biotics in the evolution and treatment of disease profoundly influenced the research and thinkmg of researchers from the success achieved by this experimental model {Reeves G, Todd I. Lecture notes on immuBology. 2nd ed: Blackwell. Scientific Publications, 1991; Neto VA, Nicodemo AC, Lopes HV. Antibioticos na pratica medica. 6th ed: Sarvier, 2007; Murray PR, Rosenthal KS, PfitUer MA. Microbiologia Medica. 5ih ed: Mosby, 2006; Trabuisi LR,
Alterthum F. Microbiologia. 5th ed: Atheneu Editora, 2008).
Antibiotics were succeeded by the development and use of antifungal, antiparasitic and antiviral drugs. The "asti" drug model became a gold standard experimental model due to huge success against anti-etioiogic agents, and was extended to diseases with unknown etiology against their physio pathologic process and to very similar autologous neoplastic cells, with less specificity, less selectivity and less effectivity as:
* Anti-allergic:
Anti-inflaromatory:
• Anti-immune (Immunosuppressive);
Anti-neopiastic (cytotoxic); and
Anti-hormone.
Thus, the new "anti" chugs brought an enormous capacity for medical intervention, with numerous benefits, with definitive and partial cures, with the prolongation of life in incurable diseases, but also with huge morbidity due to side effects related to their lack of specificity to the pathophysiology of the diseases.
The irssaie immunity The innate immunity, in addition to preventing the entry of microorganisms and preventing their establishment has another recently discovered vital function: discrimination between "self ! and "not self by the pattern recognition capability linked to the alarm and the command to start or inhibit an integrated immune response against an invading microorganism or to arrest, repair or inhibit a condition of destruction or self-aggression to the body, for example, in trauma, autoimmune diseases and allergic diseases, among others.
Ibis dual capability was previously erroneously attributed exclusively to adaptive hrun unity. The innate immunity, through its own germinal receptors, recognizes invading pathogenic microorganisms, autologous or even allogeneic neoplastic ceils, or allogeneic or heterologous transplants as "not self", identifying them as not belonging to the organism. From that moment, it triggers an alarm and a joint innate and adaptive immune response to eliminate them or suppress a response deleterious to the human or animal organism (Goidsby RA, Kindt TJ, Osborne B . Imimoiogia de kuby. 6 ed: ARTMED; 2008, 704 p; Janeway C, Travers P. Waiport M, Sihlomchik MJ. Immunobiology five. 5 ed: Garland Pub.; 2001 . 732 p.; Voltarelh JC .
Imunologia elinica na pratica medica: atheneu editora; 2009; Janeway CA. Ir . , Medzliitov R. Innate immune recognition. Annual review of immunology. 2002:20: 197-216. Epub
2002/02/28; Matzinger P. The danger model: a renewed sense of self. Science. 2002:296 (5566) :301-5. Epub 2002/04/16; Steinman RM, Banchereau I. Taking dendritic cells into medicine. Nature. 2007: 449 (7161) : 419-26. Epub 2007/09/28.; Beutler BA. TLRs and innate imimmity. Biood. 2009; 1 13 (7 }: 1399-407. Epub 2008/09/02; Moresco EM, LaVme D, Beutler B. Toil- like receptors. Current biology : CB . 2011 ; 21 ( 13 ) : R488-93. Epub 201 1/07/12) (1).
The recognition pattern of "not self, of an invasive germ is performed by sentinel cells, represented by epithelial cells, mucosal ceils, and the stromal cells, such as pericytes, dendritic cells, macrophages and fibroblasts, among others. These cells, strategically distributed throughout the body, have PRRs (Pattens Recognition Receptors) and DRRs (Danger
Recognition Receptors) and SRR (stress response receptors) which are receptors respectively able to recognize a) standard identification molecules, characteristic of a wide range of microorganisms, b) certain patterns for chemical and physical of said inert substances and changes to metabolic stress, such as release of free radicals and tissue chemical changes., caused by ionizing radiation or by chemical substances, among others and c) stress receptor signals mat identify viruses, starvation, ER stress and oxidative stress (Pulendran, B Annual Review Immunology 2015).
The PR.R does not discriminate one specific individual microorganism, but the presence of microorganisms other than the human bom-'. Each PRR receiver may bind to several different pathogens, recognizing as PAMPs (Pathogen Associated Molecular Patterns) carbohydrates, lipids, peptides and nucleic acids from bacteria, viruses, fungi or parasites that are not found in the human or animal body.
The DRRs discriminate that, there is tissue damage, a dangerous situation caused by not live or inert agents. The DRRs identify- DAMPs (Danger Associated Molecular Patterns) associated with tissue damage by toxic substances, radiation, or trauma, which cause metabolic stress, release of tree radicals and chemical changes in tissue, recognized by these receptors.
The SRRs (stress response receptors) identify' the signal of the metabolic stress caused by environment aggressions as viral infections or viral effective vaccines, amino acid starvation, ER(endoplasmic reticulum) stress, oxidative stress, through evolutionary conserved stress- sensing mechanism, that compose de integrated Stress Response ISR as recently discovered (Janeway C, Travers P. a!pon: M, SlMomchik Ml imtmmobioiogy five. 5th ed: Garland Pub.: 2001. 732 p.: Matzinger P. The danger model: a renewed sense of self. Science. 2002 ; 296 ( 5566) : 30.1 -5. Epub 2002/04/16; Beuiler BA. TLRs and innate immunity. Blood. 2009;! 13 (7) : 1399-407. Epub 2008/09/02: Moresco EM, LaVine D, Beutler B. Toil-like receptors. Current biology: CB. 201 1 :21 ( 13) :R4S8~93. Epub 2011 /07/12) ( 1).
Thus, sentinel cells via their PRRs and their DRRs, and SRRs have a role in the breakdown of which belongs ("self) and which, is does not belong (not "self) and triggering inflammation and immune response, via recognition of PAMPs of invading pathogens and DAMPs caused by neoplastic ceils, inert substances and toxic substances or modifications due to trauma, or stress response signals in infections in ISR leading to a situation of real danger to the human and animal, organism .
Immediately, these activated sentinel cells give alarm signals, triggering the innate immune response through the NF-kB (Nuclear Facior-kB) signal translation system, leading to the secretion of pro-hifiaxmnatory cytokines and the IRF signal translation system, that produces Type I alpha and 'beta interferons. These cytokines, together, acting on cells and vessels, cause a local inflammatory process, initially to contain the invading agent, autologous (tumour cell), heterologous (microorganisms, prions, grafts and transplants) or allogeneic (grafts and transplants), or to repair danger situations. This contention happens through antibodies, preexisting, opsonizing acute phase proteins and through leukocytes and macrophages, which engulf and start to destroy the extracellular and intracellular microorganisms respectively, or eliminating other etioiogic agents of any kind.
Interaction and integration of innate immunity with adaptive immunity
Simultaneously at the site of invasion, aggression and inflammation, the innate immunity sentinel ceils with the APC role (Antigen Presenting Ceils), such as dendritic cells and macrophages, phagocytosis and pinocytosis microorganisms or tumour cells, or transplanted ceils, among other aggressors and process their antigens. These APC cells pulsed by the antigens migrate to regional lymph nodes and activate them. The APC cells in reactive lymph nodes, activated and mature present the antigens to lymphocytes, release cytokines and thereby induce, coordinate, -polarize, amplify and maintain an adaptive immune response specific to the invading germs, or neoplastic ceils, or to transplanted cells, or other offending agent, allowing them to be fought and eliminated, where feasible and the consequent cure of the infection or inflammation and repair and regeneration or wound healing (1 ) (3).
Tims, these immune mechanisms fight diseases through innate and adaptive primary or secondary- responses in an integrated and synergistic way, performed by sentinels cells. APC function sentinels, and innate immunity effectors, cellular and molecular in conjunction with die cellular and molecular effectors of adaptive immunity that are respectively lymphocytes, cytokines and antibodies.
Tims, the interaction of the two immunities, innate and adapti ve, in the context of an infection, or immune response against an aggressor of any kind helps to fight the disease in an integrated and synergistic way. The integration of the two initially occurs by the action of the innate immunity cells with APC function, such as dendritic cells and macrophages, but mainly by the activity- of dendritic cells, as they are the ones that are able to initiate an adapti ve immune response against a primary infectious or parasitic agent effectively protecting the body(2, 3). !n secondary response memory, ceils govern the silent immunological process that induce- full protection (1.,2,3, 14,26,38,5436,57,58,65)
Macrophages also function as APC cells, but are more specialized and involved as part of the effector loop in phagocytosis and in the elimination of microorganisms. B lymphocytes, when mature, are also APC ceils and its most well-known action is the presentation of antigens to the T lymphocytes, within the framework of cooperation of bom lymphocytes to produce antibodies against T-dependent antigen, and the secondary antibody response in lymph nodes and bonne marrow. Macrophages, like other myeloid cells, are also involved in suppressing immune response in mostly in chronic infections or in acute infections, in these case of chronic infections or tumours, its performance is unfavourable to the defence of the organism because it suppresses the immune response and create a chronic infection or tumour facilitation.
When co-stimulatory molecules are not expressed on the APC ceil surface, by the absence of the alarm signal characterized by the lack of activation ofPRRs, DAMPs and SRR by PAMPs, DAMPs and SRSs, only the first signal occurs, given by the ICR. After the TCR binds with the antigen, in the absence of the second signal, the T lymphocyte becomes tolerant to the specific antigen shown and aborts the immune response.
On. the other hand, the CD 40L molecule of activated T lymphocytes, when it binds to the CD40 molecule on the APC ceils, significantly increases the expression ofCDSO and CD86 molecules, increasing the current response, which thus occurs only when the adaptive T response is already engaged in defending the body. The third signal given by cytokines such as IL-j , is given usually by the APC cells after the binding of co-stimulatory molecules and the emission of the second signal. The JL-1 released by the APC ceils acts on lymphocyte ceils and leads to the complete expression of the receptor for 1L2 and to the production of 1.L2 and others polarization cytokines by virgin or memory7 lymphocytes engaged in response initiating clonal selection and expansion(primary) or memory clonal proliferation (secondary).
Therefore, the activation of innate immunity by pathogens or by aggression is the key to unleashing the second and third signals and the occurrence of a potentially effective immunity, through the full activation of T lymphocytes engaged in the response. Without the occurrence of the second and third, signal, the response is aborted and generates a tolerance specific to the antigen presented.
At the same time that the neutrophils, monocytes and macrophages initiate combat to bacteria and to other infectious agents by the linkage ofPAMPs with PRRs SRSs on antigen presenting ceils (APC), they activate dendritic cells and macrophages, local and newly arrived or best activated by memory cells. These cells phagocytosis and pinocytosis bacteria and bacterial antigens, processing them and starting the maturation process. The activated and maturing dendritic cells now migrate to regional lymph nodes to present antigens and initiate immune response against the invading agent.
PAMPs alone can remodel lymph node feed, arteriole and induce lymph node hypertrophy that, is essential for an effective primary adaptive response occurs (4. 5). In secondary responses activated and pulsed by DCs cells in inflammatory territory, effector memory CD4-CD40- L+cell migrate in a€D62P-dependent fashion into the reactive lymph nodes via H'EVs and license dendritic cells for T cell priming against weak antigen, tolerate antigens and auto antigen starting an auto immune disease or improving an immune response in an ongoing infection or neoplastic disease(4). Also in inflammatory territories effector memory CD8 T cells secrete CCL3, that in turn activate MFCs to produce TNF alfa that induce PMNNs and Others MFCs to produce ROIs and clear intracellular bacteria. Unrelated intracellular pathogen sensitive to ROIs can. also be clear by bystander activation in overlapping diseases or overlapping immune responses (6, 7).
The mature antigen -pulsed APC cells, especially dendritic ceils, in lymph nodes, collaborate wills the T and. B lymphocytes and initiate the adaptive primary or secondary response ( i). Dendritic cells are the most potent cells for the presentation of antigens and the only APC cells able to activate a virgin CD4 T lymphocyte and to start a new immune response (2,3).
After a period of approximately seven days in the lymph node, the collaboration between, blank C.D4 lymphocytes CD4-ThG), which become T CD4 Th2 or Tib, with B lymphocytes and antigen presenting dendritic cells, initiates the differentiation of specific sensitized B lymphocytes. These B cells, now activated, recognize bacterial antigens by surface
isnmxmoglobulins, collaborate with T helper cells, cells after contact with these antigens. proliferate, mature, and differentiate into plasma cells that now release specific antibodies against this bacterium in a first moment outside of follicular node in the B cell area, in activated lymph nodes and after differentiation goes inside and induce germinal centre fonnation and secondary B cells responses with collaboration with€D4Tfh and others CD4T helpers cells. In secondary B ceils responses, long lived plasma cells secrete Tcell dependent antibodies in bonne marrow, after initial production in lymph nodes (1,6) (8, 9). Infections of ail types, bacterial, viral, fungal and parasitic may, in general, in the acute phase, evolve to a full cure with regeneration and healing, or for a cure with sequelae. They can also develop into an incurable ciifonicity, with or without control of the disease, to chronicity with healing, with or without sequelae, or to death.
Polarization of the immune response The classic immune profiles known and induced by dendritic ceils by direct and indirect contact with the different cytokines and generated by T C.D4 cells are of four iypes(l(M2): a) cellular Thi profile, which generates cellular immunity mediated by cells;(13) b) humoral Th2 profile, which generates humoral immunity mediated by antibodies! 13); c) tissue or inflammatory Thi? profile, which generates inflammatory tissue immunity, also mediated by cells and cytokines, which induce an important inflammation for the elimination of certain pathogens, and(13, 14) d) Treg/Td profile, which suppresses the immune response aad controls, by inhibiting the other three profiles described above, ensuring the return of the body equilibrium state.(13, 15) e) New profiles have been stablished, as the Tfh {follicular Helper) of the humoral response (16), the Th9 profile for certain parasites like Helminths ( 17),Th22 that produce IL22 involved in Skin protection ( 17) or other profiles that may be discovered or no fully estab!ished( 18).
Thus, the various profiles ensure the defence of the organism and the elimination of causative heterologous (infectious) agents invading and colonizing autologous (neoplasia). The last classic profile ensures the termination of the immune response, die balance, the regeneration, the safe return to normalcy and it prevents self-injury and allergy and is therefore vital to -the health and preservation of the human species and animal, as much as the other profiles.
The phenomenon of polarization of the immune response is defined as the predominance of a certain, immunological profile such as Thl or Th2 at the expense of other profiles thai become secondary or null. This phenomenon happens according to the type of attack suffered by the body. That is, according to die type of infection, pathology, and. infection stage or pathology stage, the different type of immune response will be predominant, and it may be a cellular, humoral, tissue inflammatory, or immune-regulatory response, while other types of immune responses are inhibited, resulting in the phenomenon of polarizat-on.{!2)
By definition, there is a dominant profile in polarization, but other non-dominant profiles are also needed, and expressed in a complementary manner that will help eliminating the disease. For example, tuberculosis is the appearance of Thi7 ceils in the lung which allows Thl ceils to settle and may lead to cute this infection in the lung parenchyma (Siockmger, B. and Veidhoen, M. Differentiation and function of Thl 7 T cells. Current Opinion in Immunology, 19 (3), pp. 281-286. 2007). In viral infections, the CTL cells ofThi profile destroy cells infected by viruses, to eliminate the vims. However, antibodies are required to prevent the virus from infecting other healthy cells and thus preventing the spread of infection. The coordinated assembly of the two profiles is essential for the healing of certain viral infections. Certain intestinal infections by extracellular Gram-negative bacilli require, for its cure, in the final stage, besides the Tfh and Th2 profile, the generation of a supplementary Thl7 profile capable of generating a strong inflammation, necessary to eliminate this type of bacteria. (12) hi conclusion, due to the fact that fee dendritic ceils are the only professional APC cells capable to initiate a primary adaptive immune response and are the most potent in triggering a secondary specific immune response, in any profile, they are then commanding the interaction and integration of innate immunity with adaptive immunity to produce an effective immune response capable of curing a disease. Dendritic ceils in collaboration with other APC and sentinel ceils is contact wi th different aggressors in different functional states, in the inflammation sites, in the lymph nodes, in the spleen, in the mucous membranes, are able to lead, coordinate, polarize, and amplify the adaptive immune response governing them, primary and secondary, e.g., specific, for the peptides of invading pathogens, which in this case is the most appropriate for the removal of the ongoing rafeetkm( 1 ,2,3)
Therefore, dendritic cells and other APC cells are key cells of the innate immune response, since they evaluate the nature of the autologous and heterologous causative agent, i.e., the type of pathogen or colonizing cells and aided by the sentinel cells, tfeey measure and evaluate the size of the heterologous or autologous aggression, its extension, its intensity and aggressiveness, besides commanding the adaptive response with the profile and the intensity required for the elimination of the pathogen. la other words, innate immunity comexiuaiize the aggression in a primary response and recontextualize in a secondary effective one by the action of T B and some NK memory cells (19) (20) (8, 9, 20-31)
After differentiation, a re-differentiation can occur, induced by the microenvixonment and/or the type of antigen or its presentation, in which a Thl or Th2 profile can be exchanged for an inflammatory profile or an immunosuppressant profile or vice versa. This extreme plasticity of the immune system to differentiate or re- differentiate in either direction, indicates a strategic window for manipulation of the immune system, during infection, when the direction taken by the polarization is not the best one for curing the infection process or neoplasia (32).
As an illustrative example, we have what happens in a severe infection or septicaemia, that induce sepsis with massive inflammation caused by cytokine, induced by the large number of microorganisms which, touch the sentinel cells throughout the body, induces also a Thl? a profile, which in turn increases the inflammation more and therefore becomes detrimental, leading to tissue destruction, rather than inducing healing and paradoxically inducing late immunosuppression by the Treg/Trl profile and exhaustion state . In these cases the Thl7 profile, by tissue destruction and the amplification of inflammation, is implicated in the generation of clinical complications such as severe ARDS (acute respiratory distress syndrome in adults), lung shock, renal failure, or shock, that compromises healing (4, 33, 34).
The re-differentiation of polarization for the Thl or Th2 profiles, with the inhibition of massive inflammation, is the logical and strategic path for a designed or prepared immunotherapy to try to resolve this dramatic and deadly type of situation, during a severe infection or sepsis, which has a significant, mortality and morbidity and. for which antibiotics and other antimicrobials, in current patterns such as single mode, have disappointing anti -infective results. The same example applies to serious intra cellular bacterial fungal, viral and parasitic infections, with extensive tissue destruction and massive inflammation, usually of poor prognosis.
The use of adjuvants to stimulate immune response
The human and animal organisms do not usually produce antibodies against soluble proteins, necessitating the use of so-called nonspecific or unrelated adjuvants to obtain the desired immune response. These adjuvants used since the dawn of immunology, in immunizations and in vaccine applications, were arid are made up of parts of microorganisms, mineral oils and other substances that activate the innate immunity, which then gives the alarm and control necessary for the development of desired immune response to the protein or to the vaccine in question (GOLDSBY RA, KINDT TJ, OSBORNE BA. 1MUNOLOGIA DE KUBY. 6 ed: ARTMED; 2008. 704 p) ; {ianeway C, Travers P, alport M, S!faiomchik MI. imnumobiology five, 5 ed: Garland Pub.; 2001. 732 p.); (VGLTARELLI JC . IMUNOLOG1A CLIMCA NA PRATICA MEDiCA: ATHENEU EDJTORA; 2009); (Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annual review of immunology. 2002;20: 197-216. Epub 2002/02/28.); {Matzmger P. The danger model: a renewed sense of self. Science. 2002 ; 296 ( 5566) : 301-5. Epub 2002/04/16.): (Steinman RM, Baachereau J. Taking dendritic ceils into medicine. Nature. 2007 ; 449 { 7161 ): 19-26. Epub 2007/09/28,); (Beutler BA. TLRs and innate immunity. Blood. 2009 ; 1 13 ( 7 ): 1399-407. Epub 2008/09/02,); (Moresco EM. LaVine D, Beutler B. Toll-like receptors. Current biology : CB. 20 Π ; 21 { 1.3 ) : R488-93. Epub 2011/07/12).
It should be noted that the use of adjuvants for immunizalion, despite being one of the oldest features, and sti!i current, highly used and essential for vaccinations and for studies of immunology, was considered only as a useful nonspecific effect. It was not envisioned, for more than a century, its role in the innate immunity in the discrimination of what is "Self and not "Self and its unique and fundamental capacity to the survival of the human species and animals: to give the alarm signal and the command to .start or not start, or inhibit an integrated, protective or healing, innate and adaptive, immune response (GOLDSBY RA, KINDT TJ. OSBORNE BA. IMUNOLOGiA DE KUBY . 6 ed: ARTMED; 2008. 704 p); (Janeway C, Travers ?, Wa!porf. M, SlhJomchik Ml immunobiology five. 5 ed: Garland Pub. : 2001 . 732 p. ) : (VGLTARELLI JC. IMUNOLOGIA CLIMCA NA PRATICA MEDiCA: ATHENEU EDITORA; 2009); (Janeway€A, Jr., Medzhitov R. Innate immune recognition. Annual review of immunology. 2002;20: 197-216. Epub 2002/02/28.); (Matzinger P. The danger model: a renewed sense of self Science. 2002;296 (5566) : 301-5. Epub 2002/04 /16.) : (Steioman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007 ; 449 { 7161 ): 419-26. Epub 2007/09/28.); (Beutler SA. TLRs and innate immunity. Blood. 2009 ; 1 13 ( 7 ); 1399-407. Epub 2008/09/02.); (Moresco EM LaVine D, Beutler B. Toll-like receptors. Current biology : CB. 201 1; 21 ( 13 ) : R488-93. Epub 201 1/07/12).
Treatment of severe infections, sepsis, and septic shock
The current paradigm in infectious diseases is that antimicrobials are toxic selective drags that destroy or block pathogens, like bacteria, fitngus, vims and parasites, with little damage to the host and are responsible for the clearance of these agents . For this reason, they are traditionally employed in monotherapeutic approaches. (Reeves G, I'odd S. Lecture notes on. immunology. 2nd ed: Blackwell Scientific Publications, 1991; Neto VA, Mcodemo AC. Lopes HV.
Antibioiicos na pratica medica. 6th ed: Sarvier, 2007; Murray PR, Rosenthal KS, Pfalier MA. Microbiologia Medica. 5th ed: Mosby, 2006; Trabulsi LR, Aiterthum F. Microbiologia. 5th ed: Atheneu Editors, 200S).
The treatment of severe infections, sepsis, and septic shock, combine more titan, one antibiotic, avoiding microbial resistance in combination with support measures to prevent or limit SIRS, ARSD or MODS or helped by preventive vaccines. Therefore, the current research is mostly focused on new antimicrobial drugs, drugs that prevent microbial resistance, and sew medicines or biological agents to inhibit or control proinflammatory and immunosuppressive
microenvironmcnts, and vacctnes.{34-4! )
Paradoxically, the detailed analysis of the experimental model, that gave rise to the current paradigm in infectious diseases reveals an unexpected and not foreseen different conclusion: In that model there are 3 players in the Petri dish: the pathogen, the antimicrobial drug and an inert culture medium that don't interfere in the interaction of die first 2 components. In that case, if the drag is effective we can say that the antibiotic made the elimination or clearance of the pathogen in vitro. However, in the in vivo correlated situation, there are also 3 components: the antibiotic drug, the pathogen and the human or animal bodies, that are not an inert medium, and have an immune system with the same task of the antibiotic, that is, they also block and combat the pathogen. We cannot translate the conclusion of a system in vitro with 3 components and .2 variables to a system in vivo with .3 components and 3 variables. They are not scientifically comparable and the conclusion in vitro cannot be translated to the in vivo system to explain cure.
For that reason, in the case of the antibiotic that can eliminate the isolated bacteria in vitro, it is not possible to say thai the same antibiotic is responsible for the clearance of this pathogen or responsible for the cure of the infection in vivo when its occurs. The only conclusion that can be made in that case is: the success of the antimicrobial treatment in the clearance of the pathogen and in the cure of infection in vivo depends on the joint action of the antimicrobial drug and the immune system. in strong support of this view, the immune system is deficient in the extreme of ages, dysfunctional in elders and immature in the first years of age. In this periods of life, infections are usually more severe and frequent, and mere are also a higher rate of morbidity and mortality, even when antibiotics are used in correct indication, dosing and timing.
Also in the ease of severe secondary immune deficiencies, like terminal AIDS, terminal oncologic patients, other terminal immune compromised patients and in terminal severs primary immune deficiencies of any kind, cure with antimicrobial drags are not possible. Irs. the immune compromised host, the antibiotics are used in higher doses compared to the immune competent patient for the very same clinical or veterinary condition. In the undeveloped world., where most of human population lives, malnutrition compromises the fitness and functionality of the immune system.
The lack of sewerage and drinkable water supply submits these populations to constant aggressions by innumerable pathogens, compromising the efficiency of the defence system and provoking disease. This constant aggression and frequent illness create an unhealthy positive feedback loop, compromising continuously the immune system and health. Finally, the lack of protection from environment aggression also weakens the body and immune system. These three conditions combined, in a synergic way also create an unhealthy positive feedback loop. that severely compromises the immunological system, and decreases the efficiency of antimicrobial drugs, shortening the lifespan of these populations. There is no available data supporting of the isolated action of antimicrobial medicines in vivo without the collaboration of the immune system, since humans and animals cannot live without a functional immune system and once invaded the immune system react by innate and adaptive responses that only finish after the clearance of the pathogen and the end of tissue repair and the return to homeostasis (7,8).
In agreement with this interpretation, there is no clear evidence in the literature of clearance of pathogen in vivo by the sole action of antibiotics or antimicrobial drags, in conclusion, without a functional immune system, it is impossible to cure severe infections with antimicrobial drugs in the monotherapeutic approach, in contrast, the cure of some infections is possible without antimicrobial drugs. Altogether, these evidences pointed to a definitive and significant role exerted by the immune system in the cure reached by antimicrobial drugs in vivo in infections (Reeves G, Todd I. Lecture notes on immunology. 2nd ed: Blackweli Scientific Publications, 1991; Neto VA, Nicodemo AC, Lopes HV. Antibioticos na praiica medica. 6th ed: Sarvier, 2007; Murray Pit. Rosenthal KS, Pfaller MA. Microbiologia Medica. 5th ed: Mosby, 2006; Trabulsi LR, Altertbtsm F. Microbiologia. 5th ed: Atheneu Editors, 2008).
A new explanation should be formulated in order to better understand the cure induced by the antimicrobial drugs in vivo, independently of the, well known mechanism of action in vitro against microbes. The inventors propose a new concept, in which the antimicrobial drags can be considered as equilibrium shifters (ES) in a host x pathogen competition, that favours the host immune system in a multivariable context. The variables are: concomitant diseases, traumas, age, sex, race, psychological health, innate and adaptive immunity, metabolism, nutrition, physiological flora microbiota, environmental aggression by drugs, and exposure to radiation, gases, pathogens and medical treatments.
What possibly occurs is that the antimicrobial drugs by their action against bacteria facilitate the work of the immune system in pathogen clearance, reverting the host x pathogen equilibrium competition and promoting the cure. The antimicrobial drags would function as equilibrium shifters of the host x pathogen competition by significantly: weakening the pathogens action and reducing their numbers is vivo and by that way facilitating the role of the immune system in microbe clearance. Alternative outcomes are death or chronic infection, regardless of the use of antimicrobial drags.
The application of this new concept in the context of the discovery of new treatments for severe or potential incurable infections/infilarnmatory' syndromes, such as sepsis or septic shock deserves some considerations. As equilibrium shifters in the host versus pathogen balance, antimicrobial drugs have a compulsory partner in vivo., the immune system. By accepting the concept, that antimicrobial drugs are not the main players in achieving cure but act as important and frequently necessary helper factors that contribute to shift the balance in favour of the host, in infeerion/inflarrursation disease, a primordial question emerges: how to change and improve an established initial exaggerated, ineffective,, improper ore deleterious IR conducting the immune system to generate the best immunological response (IR) available, innate and adaptive capable to combat and make the clearance of the pathogen and at the same time having an physiological benefic anti-inflammatory action during the course of the treated disease.
OBJECTIVES OF THE INVENTION
In general, one of the objectives of the invention is providing products comprising immunogenic compositions, in certain embodiments such compositions are combined wife one or more antibiotics, as well as methods and uses thereof for treating and/or preventing infectious diseases and preparing medicaments therefor.
It is a specific object of the present invention to provide immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of two or more Immunological Response Shifter (IRS) comprising an immune active antigenic agents that present pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS), and stress response signais(l) and one or more physiologically acceptable carriers, excipienis, diluents or solvents.
In particular, it is an objective of the present invention providing immunogenic compositions for modulating the immune system which comprise immunological Response Shifters (IRS) that have immune-active pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and/or stress response signals (SRS) selected from the group consisting of: A) antigenic agents with molecular patterns associated with, bacteria; (B) antigenic agents with molecular patterns associated with viruses; (C) antigenic agents wife molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; {£} antigenic agents with molecular patterns associated with multicellular parasites / or (F) antigenic agents with molecular patterns associated with prions.
The present invention also aims to provide uses of the above-mentioned immunogenic compositions for preparing pharmaceutical products and. methods for modulating the immune system., particularly for real-time replacement of an innefeciive immune response with an effective immune response.
Therefore, the present invention aims to provide products and methods for treating infectious diseases, including severe infection, sepis and mufti rresistant bacteria, and modulating the immune system. The effectiveness of the invention is due to a real time replacement of an ineffective immune response with an effective immune response. Such replacement made by proactively creating a new image of the aggressor pathogen to the host immune system, in order to reset lead back, control and improve the same.
Real-time replacing the ineffective immune response for a new effective one capable to change the host x pathogen equilibrium competition in favour to the host propitiating a chance of cure is the challenging task. This problem touches the Pasteur paradigm that says that, it is possible to immunize the host, to confer protection against the aggressor upon a second encounter, without significant clinical signs of the disease.
The basis of these phenomenon is the established immunological memory phenotype in T and .8 lymphocytes and. also to a lesser extent in NK ceils (7-21)), as recently demonstrated.
Altogether, these ceils may induce inflammatory innate and adaptive responses in the second contact with the antigen. That is the basis of preventive vaccines, which are the most effective medicines ever created so far. Paradoxically, the state of the art lacks therapeutic vaccines for infectious diseases.
Revisiting die paradigm of Pasteur, we can take as a model two of the most effective preventive vjrus vaccines ever developed against invariable pathogens: smallpox and yellow fever (YF- 17D). lite first eradicated smallpox until now and the second led to the development of protective immunity thai could last more than 35 years, after a single dose. A series of detailed modern scientific studies with YF-17D Yellow Fever vaccine in system biology and system vaccmology, demonstrated that virus, make contact with a wide range of sentinel and professional APC innate ceils, activating the same. Activating also multiple DC subsets by the stimulation of multiple PRRs, DRRs, stress response receptors by multiple PAMPs and DAMPs, stress signals in each DC cell ripe and subset and in multiple subsets and DC cells types and others APC cells and NK cells.
These multiple sentinel cell activation that leads to an also complex and multiple synergic DCs activation in multiple inflammatory and lymphoid territories lead to a systemic CD4 ΤΗΪ , CD4 TH2, CTL CDS and B cell and antibodies polyclonal effective responses that abrogate the viremia and make the inactivation and clearance of the virus and infected cells letting mem without the capacity to recycle and to perpetuate themselves in environment (42).
Some malfunction of the immune system due to rare genetic defects can give rise to an also rare vaccine disease that is in general very severe or even fatal, proving further evidence that the elimination of the vaccine virus as a matter of competition between host immune system and virus in a beneficial induced disease and not as a single vaccine unmuni2at.on{43). The activation context in a systemic subclinical disease is huge and complete different than a single repeated immunization with antigen vaccine these is one of the reason of the high effectively of these two vaccines! 1) (44-50)
In conclusion, an aggressive wiidtype virus would affect the host-pathogen balance in a different way than a vaccine virus, leading to a severe disease in one case and a subclinical disease in the other(l) (44-50). It is well known that an overlapping acute infection over a chronic one, such as cancer or chronic infection, can induce the cure of the underlying disease (42, 51). A strong activation can prevail over an ineffective one, improving the last one an altering the host x pathogen equilibrium competition and the outcome {42,51). It is also well known that the activation induced by the overlapping of an effective unrelated specific immune response is the best way known to rescue a state of tolerance, immunosuppression or anergy to a state of normal response (52)
In the same way, experiments with mutagenesis transforming low into high immunogenic tumours induce tumour rejection that cannot be generated with the wild tumour and, also induce CTLs against subdominant epitopes(53, 54). PAMPs alone can remodel lymph node feed arteriole and induce lymph node hypertrophy that is essential for an effective primary' adaptive response. An unrelated activated or pulsed effector memory T specific CD4+ CD40L+ migrate in a CD62P-dependent fashion into the reactive lymph nodes via HEVs and license dendritic ceils for T cell priming against weak antigen, tolerate antigens and auto antigen starring an auto immune disease or improving an immune response in ass ongoing infection or neoplastic disease (4, 52, 55). Effector Memory CD8 T cells release CCL3, that in turn activate MFCs to produce TNF alfa that induce PMNNs and Others MFCs to produce ROIs and clear bacteria. Unrelated pathogen sensitive to ROIs can also be clear by bystander activation^ 56-59). Recently, it was also recognized that the status of the rrucrobiome of the intestinal flora intervenes and can determine the effectiveness of a given vaccination.
These situations, studied in parallel, of disease and vaccine disease, isolated disease and overlapping diseases, blocked specific immune response overlapped by effective specific immune response, natural no immunogenic tumours versus mutagenic immunogenic tumours, vaccine immunization and ongoing immune response to the flora niierobiome and T CD4 Effector Memory ceils and CD8 T effector memory induced potent activation of innate cells, PAMPs effect on feeding lymph nodes arteriole and lymph nodes hypertrophy and the others studies described above, reveal very important points of the immune response in Pasteur paradigm that should, be considered for the proposal of a new hypotheses of work, destined to improve treatment of infecnons/inflammations, neoplastic, allergic and others diseases in the context of the design of new therapeutic approach.
Such important points of observations are: i- Use immune system is reactive and not proactive and it has a unique huge response potential but only use the stimulated patch by which they see the aggressor in the context of the host x parasite competition balance, In consequence, the outcome of a given new immune response is always circumstantially a fortuitous reply determined by the host x parasite competition balance and even if is efficient they are not the best possible response. In conclusion, a primaiy immune response is always a fortuitous reply possible to be improved
2- The best possible response, or protection, occurs only in secondary response due to effective memory formation after the cure of a severe disease ore effective vaccination. Thus, .memory cells are key in generating protective anmuniiy.
3- The innate response is not specific by its own nature and can hold multiple specific adaptive responses at the same time and in the same territories with synergic or antagonist effects. Because human and animal organisms can bold multiple aggressions at the same time and even in the same territory, the sinks of the innate immunity receptors recognition system recognize an expandable and changeable universe of PAMPs, DAMPs, and Stress Signals in contrast to a defined recognition of the identity of an aggressor pathogen by adaptive immunity.
4- Based on the characteristic cited above and on the study of the mechanism of protection induced by YF-17D vaccine the rational logistic to acti vate the innate immunity effectively, paradoxically should have to be based on the multiplicity and diversity of activation of different, sinks PRRs, DRRs and Stress Signals in different cellular compartments and in multiple cells sentries and APCs cell types with multiple cytokines and chemokines secretion in multiples territories lymphoid and no lymphoid to reach the best available adaptive immune response independently of tire antigenic receptors universe to be activated in the adaptive specific response.
5- lite major role of the primary response is to circumscribe the pathogen in a proinflammatory environment until an effective adaptive response takes place. The primary adaptive response in acute infection is also proinflammatory. Both can be very harmful if the contact surface is big and usually induce a symptomatic illness and can also induce a deleterious lethal systemic inflammation
6- The secondary' innate and adaptive effective responses are provided by T, B memory cells and in some circumstances by NK memory cells that give a faster, correctly polarized, more accurate, quiet, low inflammatory and protective immune response, when available. These modified secondary adaptive immune responses for its anti-infiammatory nature had to the ceils memory can effectively deal with systemic wide range of pathogen surface contact without being harmful for the human, and animal organism.
7- In overlapping situations cited above the innate territory activated of both diseases ore immune responses corporate forth© same cells sentries, APCs, with the release of common cytokines, common chemokines and will be in the same activated lymph nodes, and inflammatory territories all the scene ore battle context will be the same for the two responses. When secondary and primary adaptive response occur simultaneous the secondary adaptive immune response is the dominant immune response by the action of memory cells that reset the signal transmission in innate and adaptive cells and induce the primary responses to shift to a low inflammatory pattern in a target memory modified territory.
8- Also, these effects can be obtained by the injections of a mix of FAMFs and secondary antigens to cognate memory cells that induce a secondary immune response and activate optimally PMCs and PMNNs to clearance bacteria, sensitive to, ROIs and other mechanism and activate optimally lymph nodes and improve ongoing immune response or can induce a poor or tolerated or no immunogenic one.
In conclusion, the immune system is reactive and not proactive and the quality and effectiveness of the natural immune response depends mainly of two factors;
- First factor is the existence or not of an immunological effective specific memory that it determines a secondary or a primary immune response. In the case of a secondary response the best possible response is available and the outcome is a quiet protection., in the case of a primary response the new immune response is always circumstantially a. fortuitous reply and the outcome depends on the second factor and can be improved.
-The second factor is the host x parasite competition balance (40, 49, 53, 54, 60-78) .
Therefore, the immune system cannot improve by itself an already ongoing primary immune response and the answer for the question of how to change and improve an established initial primary improper immune response is apparently complex but strategically simple because there are only two factors determining the outcome of an immune response, in a primary immunological reply, there are only one remainder factor that is the context of the host x pathogen competition balance to be modified to possible improve the ongoing inefficient immune response. The antimicrobial di'ags acts by weakening, the pathogens action and reducing their numbers in vivo, and would function as ES of the host x pathogen competition like describe and proposal above. By this action the antimicrobial drug alter positively the host pathogen equilibrium balance and the outcome but don't alter the nature of the ongoing primary response. Following this rational analysis, it would be enough to changing the nature of the ongoing primary improper natural immune response to a secondary effective standard to be favourable to the organism. A task, that obviously, the immune system cannot accomplish without help, because it estimates an ordinated delay with, a differentiation step. How to transform in real time, immediately a primary fortuitous reply in a secondary best possible response? The answer is by the best possible secondary activation.
In order to accomplish this task, the strict reactive characteristic of the immune system in a primary response that depend mainly on the pathogen immnnogenieity and action, and on the fitness of the immune system, open the door for a proactive medical immune intervention that can use all the remainder vast immune potential of available reply to change the host x parasite competition balance in favour of the host with anew secondary standard of this initial IR. This strategical and planned immunological action must be able to reset, lead back, control, modify and improve in real time the immune system action to induce a favourable secondary specific effective IR for positively alter the context of host x parasite competition and the outcome.
The only possible answer would be changing the perception or how the immune system sees and characterizes the aggressor agent by including a great amount and diversity of new secondary' memory antigens determinants constructing anew perceived identity for the aggressor pathogen.
This new perceived identity may be built in all disease's lymphoid sites or not, or even inflammatory territories, in controlled periods, that naturally will change completely the activation by a secondary huge one. Now with a sew best secondary activation for the ongoing disease the immune system could reprogram the immune response based mostly in secondary well known antigenic determinants with a minority of primary determinants deriving from the aggressive pathogen that will generate a complete new different effective specific and well polarized iimiume response. The best possible one will, be generated with secondary tracts in the secondary resetting, low inflanunatory territories.
The sum of the total effective anti-infiatmmatory secondary response to fee new created image of the aggressor pathogen could revert all the induced tolerance, anergy, scape mechanism and could also induce a immune response to all fee weak antigens or subdominant epitopes to create the best possible effective response in a totally different poor inflammatory battle field, that create a complete new host x parasite competition balance in favour of the host. To reach this goal is necessary to create a new ES Equilibrium Shifter an IRS (Immunological Response Shifter) whose action, and creation should be based on the important and significant, observations made from the study of the Pasteur paradigm described in details above .
This new IRS for the proactive action of the proposed and planed immunotherapy must be constituted by a. vast and very diverse pathogen secondary antigen universe for which the organism disposes an effective memory repertoire. These antigens must be with priority inert and be applied in all the territory of the illness exceeding its limits.
Such antigens should be able to induce a multiple huge secondary anti- inflammatory activation to overlapping completely the primary pro inflammatory activation induced by the pathogen. These antigens should be applied each 3 to 5 days, to inhibit the immune suppressive cells generation imitating a draw out illness. The propose of this immunotherapy is to create at the biological level im new virtual but real exogenous ore endogenous pathogens full identified by the innate and adaptive immunity in his most part as a secondary and well know aggressor by memory effective ceils that will induce the best available immune response replacing the initial one. Changing the inner image of the pathogen picked-up by innate and adaptive memory cells we proactively change the context of the host x pathogen competition now in favour of the host. The reactive immune system, activated excellently by the proactive immunotherapy will real rime reprogram. reset and leads back the best available secondary anti-inSammators' specific immune response against the etioiogic agent reverting his initial advantage in an ongoing illness.
For the proof of concept that a new perceived image of the exogenous or endogenous pathogen by an innovative IRS may real time govern, reset, and lead back an already established pathological response we use some compassionated cases of reversed lethal irreversible sepsis mostly with, multi-resistant microorganisms out of the scope of the best available antibiotics used in combined fashion.
The following positive significant results of this clinical cases shown in die Examples prove and suggest that it is possible real time governing, resetting, leading back the immune system and create new secondary effecti ve, acti-inflamniatory' immune responses during the treratnient of a disease by replacing the initial exaggerated, ineffective, improper ore deleterious primary immune response one by proactively creating a new image of the aggressor pathogen.
This is the first demonstration that is possible to govern, reset and lead back an ongoing immune response in vivo in favour of the host altering positively the host x pathogen competition balance, as well as fee outcome, and also having a significant synergic effect with antimicrobial drugs.
Another object of the invention is the use of immunogenic compositions for preventing and/or treating infectious diseases. Particularly, providing methods of treating bacterial infections arid sepsis and uses of the above-mentioned immunogenic compositions for preparing medicaments and kits for treating bacterial infections.
DEFINITIONS
In the context of this patent application, abbreviations axe used several times, and their definitions, according to their usage in this application, are summarized below:
♦ IRS: Immunological Response Shifter
♦ 8CG refers to attenuated Mycobacterium bo vis. Bacille Calmette-Guerin;
« D AMPS refers to danger associated molecular patterns;
♦ DECA refers to the IRS composition la described in Example 1 of the present patent application;
♦ GM.-CSF refers to "Granulocyte macrophage colony-stimulating factor"; * PAMFS refers to pathogen-associated molecular patterns. • PFXJ: plaque forming units.
• PPD refers to purified protein derivative of M. tuberculosis;
♦ PPD refers to the fraction of the purified protein extract culture of Koch's bacillus ("Purified Protein Derivative"). The PPD is the major antigen of Mycobacterium tuberculosis;
♦ TDCI50 is a unit for quantification of viral particles and is the infectious dose in 50% of ceils in a tissue culture:
• Koch's Tuberculin refers to inactivated Mycobacterium bovis iysate;
♦ Units Lf or "Limes flocculation units" is the international unit for quantifying antigens in toxoid, vaccines accepted by the World Health Organization;
♦ V'iTER.: The IRS composition lb described in Example 1.
• ISR: fcteg.mt.erl Stress Response ♦ SRS: Stress response signals
• SRR: Stress response receptors
♦ ES: equilibrium shifter
DETAILED DESCRIPTION OF THE EMBODIMENTS
In a first embodiment, the invention refers to a pharmaceutical product comprising one or more antibiotics with one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3, 4. 5. 6, 7, 8, 9, 10, 1 1 , 1.2, 13. 14, 15, 16, 17, 18, 19, or 20 or more) synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria. (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeasts. (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with heimintb.es, and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipients, diluents or solvents.
Such pharmaceutical product may be a composition, a kit, a medical device or any other product which aims to deliver the antibiotics and the one or more immunogenic compositions as described above to a tissue.
The one or more antibiotics comprised in the pharmaceutical product of the invention may be selected from the following classes: Amino Acid Derivatives, Aminoglycosides, Aureolic Acids, Aziridioes, Ansamycias, Benzenoids, Carbapenems, Cephalosporins, Coumarin- glyeosides, Diphenyl Ether Derivatives, Epipolvlhiodioxopiperazines, Fatty Acid Derivatives, Glucosamine, Glycopeptides, imidazoles, indol Derivatives, Lipopeptides Macrolactams, MacToHdes, Nucleosides. Penicillins and Cephalosporins (beta-Lactams), Peptides, Peptidyl Nucleosides, Phenico!es, Polyenes, Polyethers, Pyridines and Pyrimidines, Quinolones and Fluoroquinolones, Statins, Steroids, Sulfonamides, Taxoides and Tetracyclines.
Preferably the immunogenic compositions of the present invention comprise immunoactive antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from the group consisting of: (A) antigenic agents with molecular patterns associated with bacteria; (B) antigenic agents with molecular patterns associated with viruses; (C) antigenic agents with molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; (E) antigenic agents with molecular patterns associated with multicellular parasites / or (F) antigenic agents with molecular patterns associated with prions.
Still more preferably the immunogenic compositions of this invention include pathogen- associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from among at least three categories (A), (B), (C), (D ), (E) and (F) described above.
More preferably, the immunogenic compositions of this invention include pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from among at least four categories (A), (B), (C), (D), (E) and (F) described above.
Antigenic agents of the present invention can be selected from epitopes, genetic materials, lipids, polysaccharides and/or immune active proteins of the present invention can be obtained by purification .from isolated fragments of material existing in nature or fractions denved from plant, animal or microbiological extracts, or produced by genetic recombination, preferably- derived from viral, fungal, parasitic or bacterial prion strains.
Thus, the antigenic agents of the present invention with molecular patterns associated with bacteria of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with bacteria of the genera Staphylococcus, Streptococcus, Enterococcus, Coiynebacterium, Bacillus, Listeria, Clostridium, Mycobacterium, Actinomyces, Nocardia, Eschericliia, Proteus, Klebsiella, Serratia, Enterobacter, Salmonella, Shigella, Pseudomonas, Burkholderia, Stenotrophomonas, Aemetobacter. Vibrio, Campylobacter, Helicobacter, Bacteroides, Neisseria, Moraxella, Haemophilus, Bordetei!a, Brucella,
Francisella, PasteureUa, Y ersinia, Legionella. Gardnerella, Treponema, Leptospira, Borrelia, Mycoplasma, Rickettsial and Chlamydia.
Antigenic agents with molecular patterns associated with, virus of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with virus families Adenoviridae, Aienaviridae, Bunyaviridae, Coronaviridae, Fiioviridae, Flaviviridae, Hepadrtaviridae, Deitavims., Caiiciviridae, Herpesviridae, Orthom>¾oviridae, Papovaviridae, Paramyxoviridae, Parvoviridae, Pjcomaviridae, Poxyvindae, Reoviridae, Retroviridae, Rnabdoviridae and Togaviridae.
Antigenic agents with molecular patterns associated with fungi and yeasts of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with fungi and yeasts of the genus Sporothrix, Aspergillus, Blastomyces, Candida, Coocidioides, Cryptococcus. Histoplasma and Pneumocystis.
An tigenic agents with molecular patterns associated with protozoa of the present invention may¬ be selected from, but not limited to antigenic agents with molecular patterns associated with protozoa of the genera Cryptosporidium, Cfcioapora, Entamoeba, Naegieria, Giardia,
Leishrnania, Plasmodium, Toxoplasma, Trichomonas. Trypanosoma, microsporidia and isospora.
Antigenic agents with molecular patterns associated with multicellular parasites of the present invention may be selected from, but not limited to antigenic agents with molecular patterns associated with multicellular parasites trematodes. cestodes and nematodes.
The antigenic agents of the present invention comprise protein, polysaccharide, lipid molecules and/or composite syniJietic molecules that mimic protein, polysaccharide and/or lipid molecules.
More specifically, the agents of the invention comprise immune-active antigenic protein molecules which have enzyme activity, for example kinases, phosphatases, streptoquinases, estreptodornases and Deoxyribonucl eases (e.g. domases).
The immunogenic compositions for modulating the immune sy stem of the present invention comprise from 0.001 to 500 micrograms per ml of each immunogenic agent.
Such immunogenic agents can be encapsulated in capsules, micro particles, narroparticles, coated tablets, liposomes.
Specifically, the immunogenic compositions for modulating the immune system of the present invention comprise frorn 4 to 20 antigenic agents selected from the group consisting of antigens derived from agents: doraase, !evedunn, oidiomycin. PP.D, prions, strepioquinase,
Streptococcus toxoid, diphtheria toxoid. Tetanus toxoid, Koch's tuberculin, inactivated lysate of Ascaris lumbricoides, Aspergillus spp., Aspergillus fiavus, Aspergillus fumigatus, Aspergillus ierreus, Caadida spp., Candida albicans, Candida glabrata, Candida parapsilosis. Chlamydia spp.. Chlamydia pneumoniae, Chlamydia psiitaci. Chlamydia trachomatis, Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius vermicularis, Enterococcus faecalis, Epidermophyton floccosum, Escherichia eolL Giardia lamblia, Haemophilus iafhienzae, Microsporum cannis, Mycobacterium spp... Mycobacterium bovis, Mycobacterium leprae.
Mycobacterium tuberculosis. Neisseria gonorrhoeae, human papilloma virus. Polio virus, Proteus spp., Proteus mirabilis, Proteus penerii, Proteus vulgaris. Salmonella, spp. , Salmonella bongori. Salmonella enterica, Serratia spp. , Serraiia !iquefaciens, Serratia maxcencens. Shigella spp. Shigella flexneri. Shigella sonnei, Staphylococcus spp. , Staphylococcus aureus.
Staphylococcus epidermidis, Sirongyloides stercorals. Streptococcus spp., Streptococcus bovis. Streptococcus viridans, Streptococcus equinus, Streptococcus pneumoniae, Streptococcus pyogenes. Toxoplasma gondii. Trichomonas vaginalis, trichophyton, Trichophyton spp. , Trichophyton rubram. Trichophyton tonsurans. Trichophyton mentagrophytes, yellow fever virus, hepatitis B vims, rubella virus, varicella zoster vims, variola vims, mumps virus, measles vims, herpes vims and vaccinia virus or synthetic analogues that present pathogen-associated molecular patterns (PAMPS) and/or danger-associated molecular patterns (DAMPS) associated with these antigenic agents.
In varioue embodiments, the immunogenic compositions for modulating the immune system of the present invention comprise 4, 5, 6, 7, 8, 9, 10, 1 L 32, 13, 14, 15, 16, 17, 18, 19, or 20 antigenic agents selected from the group consisting of antigens derived from agents: domase, ievedurin, oidioxnycin, ?PD, prions, streptoqsiinase. Streptococcus toxoid, diphtheria toxoid, Tetanus toxoid, Koch's tuberculin, inactivated lysate of Ascaris !umbricoides, Aspergillus spp., Aspergillus f!avus, Aspergillus fumigatus, Aspergillus terreus, Candida spp., Candida albicans, Candida glabrata, Candida parapsilosis, Chlamydia spp.. Chlamydia pneumoniae. Chlamydia psittaei, Chlamydia trachomatis, Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius verraicularis, Enterococcus faecalis, Epidermophyton fiocccsum, Escherichia coli, Giardia lambiia, Haemophilus influenzae, Mierosporum cannis, Mycobacterium spp.,
Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tuberculosis., Neisseria gonorrhoeae, human papilloma virus. Polio vims. Proteus spp., Proteus mitahiiis, Proteus penerii, Proteus vulgaris. Salmonella spp. , Salmonella bongori, Salmonella enterica, Serratia spp. , Seixatia liqwefaciens, Serratia marceacens, Shigella, spp. Shigella flexneri. Shigella sonnei. Staphylococcus spp. , Staphylococcus aureus. Staphylococcus epidermidis, Sirongyloides stercoralis, Streptococcus spp., Streptococcus bovis, Streptococcus viridans, Streptococcus equinus., Streptococcus pneumoniae. Streptococcus pyogenes. Toxoplasma gondii, Trichomonas vaginalis, trichophyton. Trichophyton, spp. , Trichophyton rubram, Trichophyton tonsurans, Trichophyton mentagrophytes, yellow fever virus, hepatitis B virus, rubella virus, varicella zoster virus, variola vims, mumps virus, measles vims, herpes virus and vaccinia virus or synthetic analogues that present pathogen-associated molecular patterns (P AMPS) and/or danger-associated molecular patterns (DAMPS) associated with these antigenic agents. A preferred immunogenic composition of the invention comprises inactivated Mycobacterium bovis Iysate, purified protein derivative of M. tuberculosis, inactivated Staphylococcus aureus iysate, inactivated Staphylococcus epidermidis Iysate, inactivated Steptococcus pyogenes Iysate, inactivated Streptococcus pneumonia iysate, inactivated Enterococcus faecaiis iysate.
Sfreptokinase/dornase. inactivated Candida albicans Iysate, inactivated Candida g'iabrata Iysate, inactivated Epidermophyton floccosum Iysate, inactivated Mierosporum canms iysate, inactivated Trichophyton mentagrophytes of the interdigitale variety iysate, inactivated enteropathogenic Escherichia coli Iysate, inactivated Salmonella bongori Iysate, inactivated Salmonella enterica iysate and. inactivated Salmonella subterranea Iysate.
A preferred immunogenic composition of the invention comprising from. 0.001 to 1 ng/ml of inactivated Mycobacterium bovis Iysate, 0.00! to 1 ng/ml of purified protein derivative of M. tuberculosis, 0.1 to 300 ug/ml of inactivated Staphylococcus aureus Iysate, O. i to 100 ug/ml of inactivated Staphylococcus epidermidis Iysate; O. i to 100 ug/ral of inactivated Steptococcus pyogenes Iysate; 0.1 to 100 pg/ml of inactivated Streptococcus pneumonia Iysate; 0.1 to 100 ug/m! of inactivated Enterococcus faecaiis Iysate, 0.01 to 10 ug/ml of streptokinase, 0.01 to .10 μ§/κι1 of doroase; 0.1 to 100 μο/ηύ of inactivated Candida albicans iysate; 0.1 to 100 ug/ml of inactivated Candida glabrata Iysate. O. i to 100 pg/ml of inactivated Epidermophyton floccosum lysate: 0.1 to 100 ug/ml of inactivated Mierosporum canals iysate. 0.1 to 100 ug/ml of inactivated Trichophyton mentagrophytes of the interdigitale variety Iysate; 0.1 to .100 pg/ml of inactivated enteropathogenic Escherichia coli Iysate; 0.1 to 100 pg/mi inactivated Salmonella bongori iysate, 0.1 to 100 isg/ml inactivated Salmonella enterica Iysate and 0.1 to 100 Mg/ml of inactivated Salmonella subterranea Iysate.
The compositions of the present invention can further comprise excipients, such as bactericides, bacteriostats. antioxidants, preservatives, buffers, .stabilizers, pH adjusters, osmolality adjusters, antifoaming agents and surfactants, and residual antigen inactivating or fractionation agents, growth medium components and solvents commonly used in the production of vaccines and im monotherapies .
The compositions of the present invention may be a solid, liquid or gel. As used herein, the use of the term "pharmaceutically acceptable carrier" means a non-toxic solid, inert, semi-solid liquid excipieut diluent auxiliary- formulation of any type, or simply a sterile aqueous solution such as saline. Some examples of materials which can serve as pharmaceutically acceptable earners are sugars such as lactose, glucose and sucrose, starches such, as com starch and potato starch, cellulose and its derivatives such as sodium caiboxy-methyl cellulose, a ethyl cellulose and cellulose acetate, cyclodextrin; oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil and soya bean oil, glycols such, as propylene glycol, polyols, such as glycerol, sorbitol, mannitol and polyethylene esters such as ethyl laurate, ethyl oleaie, agar, buffering agents such as aluminum hydroxide and magnesium hydroxide, alginic acid, pyrogen- free water, isotonic saline , Ringer's solution, buffer solutions of ethyl alcohol and phosphate as well as other non-toxic compatible substances used in. pharmaceutical formulations.
A variety of admini&ration routes in animals or humans for the immunotherapeutic
compositions and vaccines described herein are available. The particular selected mode, will depend on the selected antigenic agents, the dosage required for therapeutic efficacy and patient to whom the composition is administered. The methods of the present invention can generally be practiced using any mode of administration biologically acceptable, i.e.. any means that produces effective levels of immune response without causing clinically adverse reactions. Such modes of administration include intradermal, oral, rectal, sublingual, topical, nasal, transdermal or parenteral administration. The term "parenteral" includes subcutaneous, intravenous, epidural, irrigation, intramuscular, release pumps or infusion. In particular, in this invention, oral, intradermal, parenteral, subcutaneous, intravenous, intramuscular, and, by the nasal mucosa and/or oral administration are preferred for administration of the composi tions claimed herein.
For parenteral adminisiration. the active Ingredients may also be dissolved in a pharmaceutical carrier and administered as a solution, emulsion, including micro-and naao-emulsions or suspension . Examples of suitable carriers are water, saline, dextrose solutions, fructose solutions or Oils of animal, vegetable or synthetic origin. Other vehicles may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like.
In a second embodiment the invention, refers to a method to treat sepsis in a human or an animal who has a bacterial infection comprising administering to the human or animal an effective amount of one or more antibiotics and one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, I I, 12, 13, 14, 15, .16, 17, 18, 19, or 20 or more) synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen- associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses, (€) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with helminthes, and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipients, diluents or solvents.
Septicemia is defined as an extremely serious infection in which one or more bacteria or microorganisms, from their entry point, enter the bloodstream and start circulating in large numbers, getting established at distant points, colonizing tissues, organs, and in the most severe cases, can successively reach most of the body surface and causing sepsis as a generalized inflammation that compromise the circulators' system. Generally, when the microorganism load is too large, a large number of bacteria, with their toxic and metabolic products, with countless PAMPS and DAMPS, stress signals touching with all the also countless FRRs and RBPs stress signal receptors of most of the body surface, while generating an extensive, intense and violent general inflammatory process, with the massive release of cytokines (cytokine storm) from the translation of all these signs.
The unfavorable evolution of septicemia leads to sepsis, through the massive release of proinflammatory cytokines such as TNFs, ILL IL18, 1L6 and others, causing an inflammatory collapse with hemodynamic characteristic alterations, such as hypotension, rapid pulse, which may culminate in septic severe shock, usually irreversible. Septicemia, sepsis are serious infections/inflammations with high morbidity and mortality. In these severe
infections/infiammation syndrome the immune system, in turn, with its compromised operability by weaknesses and blockages induced by bacteria., starts to act so as to eliminate the bacteria at any cost, through the cytokine storm and through the inflammatory Thl7 tissue profile, increasing inflammation disproportionately and therefore harming the organism (33).
In tills inflammatory tissue profile, the effector loops of innate immunity, controlled by the TCD4 lymphocytes, cause tissue damage and sometimes massive destruction, that compromise organs and tissues and that exacerbate infections, leading, for example, to respiratory failure, lung shock, and in ARDS (adult respiratory distress syndrome), also leading to renal failure and multiple organ failure.
Therefore, in septicemia, in sepsis aid in septic shock there are two variables that should strategically be considered and should be the target of an immunotherapy, so it is successful. These two variables are the huge inflammation by the cytokine storm caused by the massive spread of countless bacteria is the whole body and its connection with the PRRs, DPPs, and stress signals in DCs and sentinels cells that, induce polarization for the Thi? profile caused by the functional ^feasibility of the Thl and Th2 profiles and described inflammation settings. These variables are the cornerstone of severity, gravity, morbidity and mortality of these diseases.
Taking into account, these two variables, for an immunotherapy to be effective in these infections, it should be applied to cover the entire body surface, including the greatest number of lymphatic territories to geographically overlap with the action of the pathogen or pathogens, it should also be applied to the injured areas and to the perilesional region so that together they can cause widespread, recontextuaiizatioa, that by its action can recover the integrity of the T loop and produce a wide, extensive and intensive, anti-inflammatory effect by effector/memory T cells generated within the application sites. It should, in parallel, through the
recontextualization asd reprogramming above described with huge anti-inflammatory effect by inhibiting and decreasing cytokine storm, polarize the TCD4 response of the Thl7 inflammatory tissue profile for the humoral TH2 and cell THI profiles, further decreasing the generalized inflammation by the action of memory cells the only cells in the body capable to abrogate physiologically huge inflammations.
IF used the loop amplification by IL2 should be very low, just enough to specifically amplify the repolarization of the immune response of the inflammatory profile to the immunity profile or to Treg/TRI regulatory profile.
Thus, the recontextoalizing and the rsprogramming achieved by immunotherapy using the compositions of fee present invention to achieve a new perceived identity of the pathogen, by recovering immune cells through the anti½flammatory action of non-related specific memory T lymphocytes, by the inhibition of the cytokine stoma and also by the repolarization of the tissue inflammatory profile TH17 to elective and effective TH! and ΊΉ2 immunity profiles, will together redirect the immune response. This immune response, renewed in real time during the infectious process, in conjunction with a biological balance shifter, in the case of the use of various antimicrobial agents, have a chance to reverse the biological equilibrium at the end of the curve in which is very favorable for the microorganism, to be favorable to fee host and now have a chance of solution.
Adequacy of the protocol to the "status" of the immune system in the pathology and in the patient, being treated. in the case of septicemia and sepsis, by the own pathophysiological mechanisms, there is a breach of the integrity and functionality-' of fee T loop with an inadequate polarization for a suppressing TREG profile m cancer and for an cytokine storm and inflammatory tissue Thl7 profile in sepsis with a nearly complete inoperability of fee immune system overcome by disease. In these cases, as in the examples cited herein, the recontextualizing induced by the best available secondary achieved activation of the new perceived identity of the pathogen must, reach the whole body to reverse ail immunosuppression, tolerance and immune ignorance induced by die pathology, as well as to restore ail operational and functional capacity of the immune system to have a reprogrammed and renewed effective immune response. in a third embodiment, fee invention refers to a method to treat multi resistant bacteria infection in a human or an animal who has a bacterial infection comprising adnfensfering to the human or animal an effective amount of one or more antibiotics and one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3. 4, 5, 6, 7, 8. 9, 10, 1 1 , 1.2, 13, 14, 15, 16, 17, 18, 19. or 20 or more) synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (8) antigenic agents with molecular patterns associated with viruses. (C) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated, with, protozoa, <E) antigenic agents with molecular patterns associated with helminthes, and (f) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipiems, diluents or solvents.
In a fourth embodiment, the invention refers to a method to modulate an immune system response in a human or an animal who has a bacterial infection comprising administering to the human or animal an effective amount of one or more immunogenic compositions for modulating the immune system comprising a therapeutically effective amount of three or more (e.g., 3; 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14. 15, 16, I T, 18, 19, or 20 or more) synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen- associated, molecular patterns (PAMPS) aad/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with, molecular patterns associated wi th viruses. (€) antigenic agents with molecular patterns associated, with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, {£} antigenic agents with molecular patterns associated with helminthes, and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable earners, excipients, diluents or solvents.
It is other aspects, the present invention refers to the use of immunogenic compositions in the manufacture of medicaments and kits for preventing and/or treating of infections diseases. Immunogenic compositions of the invention are also may also be used in. the pre vention and/or treatment of infectious diseases in association with one or more antibiotics.
Properties of the Lmmusogenk compositions of the present invention
The immunogenic compositions of the present invention, have an unexpected effect on the immune response. As can be seen, in the Examples below, the immunogenic compositions of the present invention show an unexpected technical effect of causing an immune response that. involves resecting, recontextualizing, leading back, renewing and reprograraming the immune response in real tuns.
More specifically, the iniinurioiherapeuiic compositions of the present invention by creating a new identity of the pathogen perceived by innate and adaptive immunological system are capable of provoking a reset, a recontextualization a lead back of the operational action capacity of the immune system by changing the relationship offerees against the aggressors in its favor, giving the immune system a competitive advantage, which does not occur spontaneously in the evolution of disease. This recontextuaiization determines a consequent, renewal and reprogramming of the established immune response or incipiently established, or erroneously established mistakenly attacking in a dysautonomical way the human or animal body, polarizing the primary pro-inflammatory response that is always a fortuitous reply possible to be improved to a secondary, active anti-inflammatory, more effective and appropriate immune response.
This effect occurs via secondary stimulation, activation and joint action of certain components of the immune system, such as sentinel cells, antigen presenting sentinel cells, and memory lymphocytes. Specifically, the compositions of this invention properly reset the activated sentinel ceils, the activated dendritic cells and other activated APC cells, by the action of memory cells, generating a new degree and intensity of CD4 T cell with a secondary activation profile that turn to a secondary effective standard the degree and. intensity of the immune profile to properly treat the infection without causing immunological side-effects, such as inflammation.
Accordingly, the immunomodulatory antigenic compositions of the present invention, when in larger or significant amounts completely change the perceived image of the pathogen and trigger a specific secondary active adaptive immune response, desired to treat bacterial, viral or parasitic infections with a low inflammatory profile.
Is addition, the treatment with the immunogenic compositions of the present invention is capable of stunuJatmg the regenerative power of the immune system, a natural physiological property of this system providing a subsequent effect to the elimination of infectious disease and other diseases: to recover cells and tissues, by restoring organ function debilitated from trauma and damage which cause the loss of part of the organism. This property was demonstrated in the clinical cases of irreversible sepsis reported is the Examples. The patients had recover}' and regeneration of complex trauma wounds with important tissue loss, organ destruction in lungs, kidneys, liver, bones and extremities induced by CIVD, and ischemic events by low blood flow and toxicity.
Thus, the immunogenic compositions of the present invention are able to mobilize the immune system and lead to an increased regenerative power of fee body, through mobilization of stem cells or the activation of gene sets which allow the regeneration of ceils and tissues and can even reconstruct organs and their functions, and can reconstitute organic systems such as the vascular system, the nervous system and the endocrine system, among others.
As can be seen in the Examples presented, below, the im munogenic compositions of the present invention exhibit an unexpected technical effect of recontextxaalizing, renewing, and reprogramming the immune response in real time and consequently significant cure rates when compared to drugs and methodologies in the art.
In a first embodiment of the invention, immuno-moduiator agent(s) is/are used for preparing an immunotherapy pharmaceutical composition capable of inducing a new innate secondary immune response, which triggers a cascade of immune events, including the main event of activation of memory lymphocytes from the ageni(s) inoculated by human intervention and the concomitant activation by antigens present in the patient's own body, resulting in a.
reccntextuaiization, renewal lead back and reprogramming of the ongoing immune response to a particular established disease (or still in the establishment phase), generating an adaptive secondary' response specific to this disease effectively, allowing combating the pathogen in an anti-isf!ammatory way. As such, the administTation of the composition containing the agents of the present invention repolarizes or improves the polarization of the immune system in the presence of a disease when the established polarization is inadequate, by the action of the etiologic agent or colonizer. The activities of the agents of the present invention affect the shape, time, accuracy and polarization of the immune response., preferably leading to an secondary innate and adaptive immune response that it is snore effective to fight the disease, leading to a better reaction of organism itself.
The present invention provides methods to -treat bacterial and other microbial infections with the use of the antigenic combinations described. Hie present invention also provides for the possibility of adding traditional therapies to the agents of this invention, aiding the process of elimination of the etiological heterologous invading agents and of the colonizing autologous cells, through the real therapeutic potential of antimicrobial drugs, selective for the pathogens and other infectious agents. This is made possible by the principle of displacement of the biological equilibrium in favor of the patient in combination with a correct polarization of the immune response as described herein.
When the immune stimulation follows a situation of immune response, after the termination of the disease mechanism or aggression, the continued activation of the immune system by antigens or immunomodulatory1 agents of the present invention leads, through the activation of stem cells, to the regeneration of tissues, organs and systems, by mechanisms not yet fully understood, but related to healing or restitution ad integrum mechanisms observed in various medical situations.
The compositions of the present invention allow the recruiting of the maximum number memory cells, new effective virgin cells of the individual, producing more significant effects than an antibody increase as described in the prior art. The use of multiple antigenic agents with distinct enough PAMFS, DAMPS and stress signals to simulate different types of attacks that the organism suffers and to which the organism has already immunologic memory of, be it by environmental exposure or vaccination programs, allows a wider recruitment of memory cells and new effective virgins cells, enabling real-time recontsxluaiization, resetting and leading back of the immune response and thus potentially and radically altering the type of immune response and disease or illness progression that affects the individual in. a. positive, and in several cases, such amazing way as compared to the prior art. Furthermore, the present invention, unlike the prior art, applies a greater and diverse amount of bacterial components, having representatives of both intracellular and extracellular bacteria in the composition, besides components of viruses, parasites, fungi and yeasts.
The present invention encompasses more areas of the body and tissues that have sentinel aid APC cells, and preferably looks for exposure on locations close to the infection sites and other distal applications to the disease sites (as is the case in disorders or diseases that manifest themselves in specific locations of the body) to secondary reset innate system in all the places of the disease. The compositions of the present invention, when applied according to the process of using the present invention in one or, usually, at various strategic of body regions drained by lymphoid territories or primary and/or secondary lymphoid organs, or even intralesiona!, are perceived by the PRRs (pathogen-associated pattern recognition receptors) off all sentinel cells of the body.
Thus, the present invention employs immunomodulatory agents in amounts, concentrations and specific locations to recontextuaiize, reset and lead back the immune system, activating and redirecting the mechanisms for tissue repair and regeneration, as occurs during healing and regeneration of tissue, organ or system, leading to a "restitution ad integrum" or reconstitution with scar. This repair is usually triggered at the end of an immune response process, after healing die infection.
Use of the imrniaiaogenk cons positions of the present invention.
Considering the properties of the immunogenic compositions of the present invention, it constitutes another aspect of the present invention using the immunogenic compositions in the manufacture of medicaments for the prevention and/or treatment of infectious diseases.
These infectious diseases can be of viral, bacterial, fungal or parasitic origin.
Diseases of viral origin prevented and/or treated by the immunogenic compositions of the present invention can be caused by the following viruses but not limited to:
HIV, hepatitis virus, herpes virus, rhabdovirus, rubella vims, smallpox virus, poxvirus, and MorbiU i vi rus paramyxovirus .
Diseases of bacterial origin prevented and/or treated by the immunogenic compositions of the present invention may be caused by the following bacteria- hut not limited to, Pneumococcus, Staphylococcus., Bacillus, Streptococcus, Meningococcus, Gonococcus, Escherichia, Klebsiella. Proteus, Pseudomonas, Salmonella, Shigella. Haemophilus, Yersinia, Listeria,
Corynebacterium, Vibrio, Clostridia, Chlamydia, Mycobacterium, Treponema, aid
Helicobacter. Fungal diseases prevented and/or treated by the immunogenic compositions of th e present invention may be caused by the following fungi but not limited to: Candida, Aspergillus, Cryptococcus neofortnans, and/or fungi that cause superficial and deep mycosis. Diseases caused by parasites are caused by the following parasites: Trypanosoma, Schistosoma-.
Leishmania, amoebas and. tapeworm.
In one embodiment of the invention, the compositions of the present invention are administered once, sis one area of the body or in difierent sites in order to redirect the immune system with the highest possible efficiency.
The use of the immunogenic compositions of the present invention for modulation of the immune system, involving the exposure of part or all of the system for recognition of antigens in the immune system, such as dendritic cells, macrophages and lymph nodes from different parts of the body, inflammatory territories will depend on the goal imposed by fee illness being fought, and occurs preferentially through injections or use of guns, or delivery systems or controlled, mfusion or pulsed cells with in vitro antigens. The agent may be applied to only one location in the body or in several tens of locations in several forms: subcutaneous, muscular, intravenous, oral, breathable aerosol, cutaneous (dermal, patches) in organs, the viscera, or specific tissues, or in different body cavities, which can vary in number from one to one hundred (100) applications in one to fifty (50) sessions.
The antigenic compositions of this invention may also be combined with other drugs feat can weaken the reproduction, growth, or any other form of strengthening of the disease's causative agent, causing a shift of "the equilibrium in favor of the biological immune defenses of the host, animal or human. Or still in concomitant treatment.
The antigenic compositions of this invention may also be combined wife other procedures such as. but not limited to, antibiotics chemotherapy, therapy with antibodies and antisera, using hormones or other physiology modulating agents (cytokines, chemokines , neurohormones, peptides), treatment with antiviral agents, use of herbal medicines, vitamin supplementation, methods of therapeutic or prophylactic vaccination (with or without cells and not limited to the type of vaccine vehicles), gene therapy, surgery or homeopathy, depending on the disease or illness being fought related to an improper or inefficient immune activity. Recenlextualszing, resetting, renewing, leading back and reprograssming the immum response.
Recontextua3iz3Bg and resetting the immune system, as explained in the text of this patent application, is achieved by means of stimulation of the immune system by antigens of different pathogens not related to fee pathology to be treated, for which the human or animal, preferably, already has an immunological memory for totally changing the inner perceived primary image of the invader pathogen to a new secondary effective proactively induced one.
These varied and multiple antigens, in number greater than fi ve, with, multiple PAMPs DAMPs and SRS induce in the sentinel cells and in the APC cells, especially in dendritic cells, an intense secondary activation allowing the mobilization of these memory CD4 and also CDS memory or eventually NK memory cells and lymphocytes specific for these antigens at. the site of application.
These stimuli m ast be capable of causing an intense, strong and effective secondary specific immune response to these antigens of the new identity at the site of application, in the regional activated lymph nodes, in the lymph nodes at a distance and a systemic mobilization of the immune system so that it can, in parallel cause an effective secondary response capable of eradicating the specific pathology in progress.
The innate and adaptive secondary nnmune response caused intentionally by the composition of the present invention should encompass the full extent of the body area affected by the condition being treated and even exceed it if possible to be able to activate the sentinel and APC cells in the number and intercity that would be needed to properly address the aggression caused by the pathogenic disease to be treated, and activating and triggering the best specific adaptive secondary response, effectively and property sequentially polarized, in order to cure the condition being treated.
Thus, the innate and adaptive response induced by the present invention will geographically overlap the condition being treated and by its intense and extensive secondary activation will correct the inefficient activation, puiposely limited by the action of the pathogen that overcomes the body's defenses, by preventing competition, its proper mobilization and development of an effective adaptive response according to its greatest genetic and biological potential. This ideal activation should also reverse the immunosuppression, the tolerance and escape mechanisms established by pathogens because it is known and proven 'that an unrelated strong and intense immune response, that fully covers the response to be corrected., through the activated cells and cytokines of the immune system, will correct these deficiency situations efficiently.
Effector cells and memories of specific antigens of the present invention, activated and generated at the site of application of fee antigens, will, via the bloodstream, enter the already activated lymph nodes by HEVs, which drain the region affected by the disease and will enable, in a strong and intense way induce fee activation of ail the existing dendritic cells there.
Therefore, they will lead to an activation of the entire lymph node, causing it to grow with increased irrigation, increasing its size and making it a reactions! lymph node capable of provoking an immune response against, weak antigens, which by themselves are not capable of causing an immune response. PAMPs alone can remodel lymph node feed arteriole and induce lymph node hypertrophy that is essential for an effective primary adaptive response and also for secondary- immune responses
This adjuvant effect, well known and demonstrated experimentally and clinically, of the effector/memory T lymphocytes, will oppose the action of the target causative agent thai is blocking the required activation of the lymph node for the development, of an immune response that is necessary to treat the disease in question. That, exclusively for the purpose and by the action of the present invention, through its potent antigenic composition, may occur that the sentinel cells and dendritic cells and macrophages of the immune response will be the same for unrelated antigens and to the pathological antigens, but from this action, will be intensely and. properly activated. Dendritic cells strongly activated by multiple antigens, have a slow metabolism and ideally present all dominant and subdoraisant epitopes of the causative agent, by the known "helper" effect, mobilizing all possible and available T lymphocytes able to specifically recognize antigens of the autologous or heterologous pathogen, to be treated and to react against it.
The areas of the inflammatory process and lymphatic territories are exactly the same. The inflamed area, through the anti-inflammatory action of specific memory ceils, unrelated. mobilized by the present invention by their antigenic composition, will block the
inflammasGmes and exert an anti-inflammatory action that will correct the pathological inflammation responsible for the morbidity of the disease and which was caused by its etiological agent. For the memory effect it's important to note that this known action of the memory T cells is the major responsible for the fact that a second contact with any pathological agent, after an already established immunity, is asymptomatic, without causing a disease.
The lymphatic territories are exactly the same, only sow intensely activated and with the necessary alarm signal caused by the present invention, to cause any immune response, even for a weak antigen, similar to what occurs with dendritic cells common to this invention and to the autologous or heterologous etiological agent to be fought. Lymphokmes and innate cells that command an effective secondary response will be the same and the T lymphocytes specific against the etiologic agent, to be fought, will "hitch a ride" on this ideal microenvironmeni for holding an effective immune response.
The dendritic ceils activated by the present invention, can capture the antigens of the etiological agent to be fought at the site of the pathology and in the related lymphatic territories and be in contact with the pathogen specific TCD4 lymphocytes, in a correctly and ideally enabled lymphatic system. The role of the dendritic cells activated and matured with fee TCD4 specific to the etiologic agent, occurs in a microenvironment conducive to conducting an immune response, with all the genetic and biological potential of the host organism's immune system.
These dendritic cells at the site of the pathology and at the lymph nodes will properly gauge the severity, extent, intensity and type of aggression, activating, inducing, coordinating, polarizing, leading and maintaining a new effective adaptive immune response., whose effector loop, with tiie collaboration of the cells and effector molecules of the intense and properly activated innate immunity may be able to eliminate the causative agent to be fought. So the answer is reprogrammed and lead back as noted above, reversing the biological balance in favor of the host, which until then was under the yoke of the offending autologous or heterologous agent.
Such action may occur with or without the help of biological balance shifters such as antibiotics drugs, capable to block, weaken or neutralize the effects and potential of the etiological agent, allowing the immune system to have a chance to heal the pathology that is the target of the treatment. Once triggered by any etiological agent, the immune system will only stop responding when the etiological agent is eliminated or the organism passes sway, this way the invention will help avoid the latter option, or it will improve the patient's condition if there is a chronic disease that cannot be cured.
Thus, the action of the compositions of the present invention intentionally and strategically superimposed over the entire area under the action of the agent to be fought, will recontextualize the immune system by activating the PAMPs and DAMFs in the sentinel cells and common APCs and by the unrelated specific secondary adaptive immune response. This intentionally induced immune response will efficiently activate the whole lymphatic territory and the organic territory affected by the etiological agent, in the recontextualized area and in the bulge, and within the context of a greater immune response, stronger, more intense and more extensive secondary anti-inflammatory nature of the target immune response will be, as described, reprogrammed and efficiently renewed within the scope of a greater chance for the host, now with a chance of reversing the biological balance in its favor,
Rationale of the therapeutic protocol
Be therapeutic protocol of the present, invention designed to be applied in cases of bacterial infection and septicemia must:
- be applied in most strategic lymphatic regions of the body or infection, in the cases described herein, more than 1.0 lymphatic territories have been. hit. It must be applied within the infected and periJesionai areas.
- the immunotherapy formulation must contain at least 5 antigens so it contains PAMPs and DAMPs so as to be able to recontextuaiize the immune system.
- the application area mast overlap, cover, and overcome the whole extension of regions dominated by the infection.
- the antigenic stimuli must be repeated every 4 or 5 days in order to avoid the generation of suppressor cells capable of aborting the new desired immune response or to suppress an achieved repolarization. - the treatment must be maintained in Ms manner until the end of the infection, or to the healing of fee wound, organ or system.
- m practice, 1 to 3 ml of this irmmmofeerapy must be applied to 10 or more lymphatic territories. This invention should be jointly applied in intra and extra lesion areas damaged by infection.
Irs summary, the immunotherapy is "systemica!!y" distributed in several (at least ten) lymphatic territories, peri- and mtra-lesion with a volume able to disrupt and destabilize the lesion from the domination of its micro and macro environment or cover the area significantly affected by infection and inflammation, as well as to restore the microenvironment that is favorable to the immune response of the organism. It will be applied every 4 to 5 days.
In sepsis, severe sepsis and septic shock, the use of low doses of exogenous mterieukin-2 should be avoided. The use of low doses of exogenous interleuksn-2 hi severe infections
uninterruptedly should be carefully evaluated when a amplification of the immune loop is needed.
.DESCRIPTION OF THE FIGURES
The following figures are part of this report and are included here to illustrate certain aspects of the invention. The object of the present invention may be better understood by reference to one or more of these figures in combination with the detailed description of the preferred, embodiment presented here.
Figure 1 shows images ofExamie 2. A I , .A3 and A4 show wounds after surgical cleaning on January 29, 2011. It's possible to notice injury of polytrauma associated with sepsis caused by mu!ti -resistant strain and major tissue loss that continued to perform poorly with a winy general appearance without any appearance of healthy granulation tissue. It is possible identifying, in X- Ray on January 29, 2011 (A2) fee external fixation of the femur after surgical procedure. On February .2, 201 1 (5 days after starting the treatment) the patient presented complete recovery from sepsis and received ICU discharge (BL B2 and B3). in B l to B3 it is possible to identify healthy granulation tissue characteristic of the second intention healing process, in C I (01 March, 201 1} it's clear the improvement of the leg injuries described in A! - A4, that's the reason why patient was discharged from hospital on IS March, 2011. In Dl (medial site) and D2 (lateral site) is possible to verify the complete recover}' from complex wound of polytrauma associated with: severe sepsis caused by multidrug-resistani Acinetobacter baurmamii and osteomyelitis. These data strongly suggest a decisive role of the DECA inamunotherapy.
associated with debridement and antibiotics, to cure the clinical scenario, in a relatively short time, making possible not only the patient survives a natural disaster but also walk again without crutch or cane.
Figure 2 shows images of Example 3. A Chest CT scan (Al aad A2) of 01/1 1/201 i before muriunotherapy and CT scan (81 and B 2) of 04/1 1/201 1 after immune treatment performed in CMS patient, in Al and A2 is possible to identify whitish areas (circled) characteristic of infection. In BI and B2 is clear the disappearance of whitish areas and recovery of the !ung parenchyma which the image became darker. These data show a recovery of aspiration pneumonia with the combination of immunotherapy with antimicrobial treatment.
Figure 3 shows images of Example 4. An X~Ray (Al) of 24 April 2007 (3 days after immiuioiherapy starts} and CT scan (B I to B6) of 27 April 2007 it's easily to identify critical SARS condition under septic shock. X-Ray (CI) of 06 May 2007 evidences complete recover after immune treatment performed in AMB patient. In A I is possible to identify whitish areas (circled) characteristic of infection. In B i - B6 the clinical status is so critical that whitish areas barely allow to identify anatomical contours our parameters (circular). In C I is clear die disappearance of whitish areas and complete recover}' of the lung parenchyma, without sequels, which the image became darker. These data show a recovery of sepsis associated with SARS, CTv D., hepatic and renal failure with the combination of 6 sessions of immunotherapy with antimicrobial treatment in 15 days.
EXAMPLES fa order to allow a better understanding of the invention and clearly demonstrate the technical progress achieved, the results of the various tests conducted with respect to this invention are shows below as examples. These Examples are presented for illustrative purposes only and should not he regarded in any way as limiting the scope and range of the invention.
Example 1: Immtmogenk Compositions
In order to achieve the recontextifalizing, renewal and reprogranirning of the immune response in real time according to the innovative concepts described in the present invention, an expert skilled in the art can design different and distinct compositions, combinations or formulations of products, which fall within the scope of the invention.
As described, for such compositions to meet the technical requirements for the advantageous or unpublished results in treat a number of diseases and illnesses, they must have a high diversity of antigens from pathogens, so as to get the maximum synergistic effect in binding the PAMPs and DAMPs to their receptors and allowing the achievement of a high degree of activation of the innate immunity in the sentinel ceils (with or without ATC function) thereby allowing the reeontextualizing, renewal and reprogrammiog of the immune response in real time.
Such compositions should preferably use antigenic agents for which most people, because of previous contact, would have memory clones of in their immune system capable of inducing a broad anti-irtflamraatory action in parallel to rscontexiuaikarion . For mis, antigenic agents should preferably be selected that:
♦ correspond to the most common infections contracted by the individual from childhood to maturity (when the animal or die human being acquires its "repertoire of immuniiy").
♦ are used in immunization programs such, as childhood vaccination programs against, endemic and'Or epidemic diseases.
♦ those from organisms of potentially pathogenic microflora, especially of the gastrointestinal tract where the memory lymphocytes play an active dynamic barrier ensuring the survival of the individual.
♦ Ideally each of the antigeni c agents should be present in a concentration of 0.001 to 500 micrograms per mL. In accordance with these concepts, several formulations have been developed, using antigenic agents m their already available, safe, and approved forms for use in human vaccination programs or allergic response tests and immunity assessment tests.
Therefore, we present die following several examples of compositions which fall within the scope of the present invention, without however the intention to limit it, since the present invention and its concepts allow for the design of immunogenic compositions comprising a. very laxge number of combinations of antigenic agents.
Composition la (DECA composition):
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Composition 12:
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Composition 17:
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000075_0002
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Composition 35;
Component i Concentration
Inactivated Candida albicans lysate, inactivated Candida parapsilosis j 6.94 pg/mL
Figure imgf000083_0002
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
When there are parasitic diseases, associated or to be fought, the formulations will preferentially contain antigenic agens of parasitic origin. In this case, according to the concept described in the present invention, the formulations should comprise antigenic agents originating from the most prevalent parasites for which the indi viduals have more- memory cells, according to the geographic distribution and the local and regional human development (developed or non- developed countries). Such parameters are determinant for the occurrence of these parasites and the existence of corresponding memory ceils in the immune system of the population of a given region.
Composition 37; Association of Composition 2 with:
Figure imgf000087_0001
Composition 44: Association of Composition 9 with:
Figure imgf000088_0001
Composition 50: Association of Composition 15 with:
Figure imgf000089_0001
Inactivated Ascaris Iumbricoides iysate 400 .ug/mL j Inactivated Strongyloides stercoraiis Iysate j 400 pg/rnL
Composition 56: Association of Composition 21 with:
Component 1 Concentration
1
Inactivated Toxoplasma gondii Iysate 400 pg/mL inactivated Entamoeba histolytica iysate 400 μg/mh
Inactivated Giardia laroblia iysate 400 pg/mL
Composition 57: Association of Composition 22 with:
Component Concentration !
Inactivated Strongyloides stercoraiis iysate 400 pg/mL
Inactivated Cryptosporidium spp. iysate 400 pg/raL
Inactivated Entamoeba histolytica Iysate 400 pg/rnL |
Composition 58: Association of Composition 23 with:
Component Concentration |
.Inactivated Ascaris Iumbricoides Iysate 400 .ug/mL inactivated Toxoplasma gondii iysate 400 pg/mL inactivated Enterobius vermicularis Iysate 400 pg/mL :
i
Composition 59: Association of Composition 24 with;
Component Concentration !
Inactivated Entamoeba histolytica Iysate 400 pg/mL
Inactivated Giardia iamblia Iysate 400 pg/rnL inactivated Ascaris Iumbricoides iysate 400 pg/inL
Composition 60: Association of Composition 25 with
Component Concentration
Inactivated Strongyloides stercoraiis Iysate 400 pg/rnl.
Figure imgf000090_0001
Figure imgf000091_0001
Composition 65: Association of Composition 30 with:
Figure imgf000092_0001
Figure imgf000093_0001
Example 2: Treating :
Patient data
Patient J-P. 58 years old, male.
Principal diagnosis
Septicemia.
Secondary diagnoses
Polytrauma with:
« Comdex infected wounds with major loss of tissue of approximately 40 cm. ♦ extensive infected tissue necrosis with indication for amputation of the left lower limb, infected grade IDS open fracture with osteomyelitis of the left, femur with lateral exposure.
* open wounds, infected cut-contusion without possibility of suture on the left, arm, back of the left foot and on the right lateral malleolus region.
Identification and summary of the clinical history
On January 12, 2011 the patient was admitted to the intensive Care Unit of the Octavian Constantino Hospital das Clinicas of Teresopoiis, victim of a. landslide with a grade ΠΙ b open 'fracture of the left: femur with the exposure of the lateral cut and medial cut-contusion with an extension of 40 em in depth that communicated with the exposure of the side. Lacerations, contusion on the left arm., back of the left, foot and right lateral malleolus region. Evolved to a sepsis scenario in 24 hours, with microbiological, identification of Pseudomonas aeruginosa.
Conventional proposed and realized treatment
External fixation of the femur in the emergency room, administration of cimdamycin, vancomycin and eefepime, associated to a daily surgical debridement.
Results of the performed conventional treatment
Initially, it improved the septic scenario, followed by the evolution of the infection of the left lower limb with extensive areas of muscle necrosis with a high risk of amputation. 15 days after the admission the sepsis got worse, with febrile episodes of 39° C, profound anemia (receiving transfusions) and exchange of the antimicrobial medication to Tazocim. The patient was transferred with an aerial mobile ICU to Sao Paulo under medical supervision.
The completion of conventional treatment sho wed a relapse in sepsis and increased necrosis of the left leg with an indication for amputation.
Proposed DECA treatment associated with conventional surgical treatment
The patient was admitted to the iCU of Hospital Alemao Oswaldo Cruz for debridement and application of treatment with DECA which took the following form: • Application of 1.8 cc of the DECA composition divided into 2 applications of 0.9 cc per composition along the 10 main lymphatic territories.
● 3-4 cm distance margin between applications to facilitate the reading of the evolution of the treatment at an interval of 4±l days. These applications were made together with the surgical debridement (on average 1 to 2 times per week).
• Administration of 36 extra perilesional compositions of I S cc of each DECA in two applications of 0.9 cc per set, skirting the following open injuries without possibility of suture: the left inguinal region, the lateral side of the left, thigh, the anterior left thigh and medial aspect of the left thigh, instep region and left lateral malleolus of the right leg.
• Application of recombinant human interieukin-2 at low doses, at a receptor saturation level with a concentration of i to 2 million units per m2 of the patient's body surface located in the region of the extra DEC A applications. 3 million daily units were subcutaneously injected in the left thigh or inguinal region for the pacient.
• In the exposed regions 15 compositions DECA were applied, 1.8 cc each, for infiltration of exposed raw areas.
• This extensive immunotherapy was always applied in the operating days of cleansing and surgical debridement under general anesthesia.
Thus, the first phase of immunotherapy began on 29 January, 2011 and ended on 19 March. 2011 totalling a total of nine DECA applications in. periods ranging from one to two times per week, once the cleaning and debridement schedule was being followed, in the operating room (due to the severity of the pain and risk of infection by the broad extensive exposure of internal tissues in the raw areas).
Results of the treatment with DECA associated with surgical debridement αηά antibiotic therapy
Initial assessment of the patient's injuries in the operating room on 29 January. 20.1 1 showed all wounds bleeding with many clots, with extensive areas of necrosis and foul-smelling pus. After surgical cleaning, tissue continued to perform poorly with a winy general appearance without any appearance of healthy granulation tissue (Figure .1 - A L A3 and A4). As described, the DECA .immunotherapy was applied to these areas. It is interesting to note that on this occasion cultures of internal secretions and tissue fragments were perforated.
After 24 hours the first assessment of the surgical treatment associated with DECA
immuBOtherapy was made and it demonstrated that: red lesions, with the appearance of healthy granulation tissue, with few necrotic areas with sparse secretion without foul odor and so active bleeding. The lesions were cleaned and the DECA urmumotherapy was applied as acted above. On this occasion the antibiotic therapy was changed to Tazocim Meronem, Cubicin aid Rifanrpiein pending culture results.
On 01 February 201 1 the result of the cultures from the injury area., peripheral blood and central catheter showed:
• in the wound of the left thigh isolation of multidrug-resistant Pseudomonas aeruginosa, rnaltiresistant Acinetobacter baunnamii sensitive only to polymyxin B aid multiresistant
Proteus rmrabiles.
♦ in the peripheral blood and in the centra! catheter the isolation of muitidrag-rcsistaat
Acinetobacter baunnamii sensitive only to polymyxin B.
Conclusion: These results demonstrated that die poor prognosis of injuries in the left leg led to a new sepsis episode with Acinetobacter baumiamii and because of its multidrug resistance and sensitivity only to polymyxin B, did not respond to treatment with intravenous Tazocim. On the other hand, it strongly supports a beneficial effect of the DECA composition in joint surgical treatment in tine local and systemic protection against this infection, since there was
improvement in systemic infection and injuries before the application of polymyxin B could neutralize this etiologic agent.
That day, Meronem was exchanged for 20,000 ίϋ/kg twice daily of Polymyxin B without changing the other medication.
On 03 February, 201 L it was found that the combination antibiotic therapy, debridement and DECA immunotherapy caused the remission of the septic scenario, which allowed the transfer of the patient from the ICU to the. ward thereafter (Figure 1 - Bl , B2 and B3). On 06 February. 201 1, given the toxicity of Polymyxin B administration and other antimicrobials, the patient presented a picture of acute renal failure with oliguria. As a consequence, on the period between 06 February, 201 i and 15 February, 2011 (12 days) administration of these antibiotics was suspended, with Limezohda (Zyvox) being introduced for protection against a hospital staphylococcal contamination. On 15 February, 2011 the complete remission of renal failure in the patient was confirmed. In this 12-day period, with only the combination therapy of debridement, antibiotic prophylaxis and DECA
immunotherapy, the patient showed excellent overall progress of the infectious and injuries being, after this period, able to withdraw the external fixator, have a surgical cleanup, and introduction of an internal rod for fixing the fracture on a surgery performed on 17 February, 201 1 . Thus, in this period, together with orthopedic surgery, there was a significant reduction in raw areas without skin with extensive tissue regeneration and no new infections.
The patient was discharged on .15 March, 201 1, with complete cure of the infection of all complex injuries and wounds, including osteomyelitis. The patient was discharged without antibiotic therapy.
Conclusion of the case
The existence of a severe and widespread infection and of a complex wound infected with with multidrug-resistant Aemetobacter baunnamii sensitive only to ροΚτηνχίη S which was controlled without specific antibiotic therapy with broad progression to the healing of sepsis, of all exposed lesions, and of osteomyelitis, strongly suggest a decisive role of the DECA immunotherapy, associated with debridement and antibiotics, to cure the clinical scenario, in a relatively short time.
Table i. Result of die association of DECA immunotherapy, antibiotics and surgical debridement for sepsis and severe infection of complex injuries.
Figure imgf000098_0001
Example 3: Treating sepsis associated with urinary infections and concomitant oropharynx with terminal gastric carcinoma
Patient Information
Patient CMS - female, .38 years old.
Diagnosis
Terminal gastric carcinoma with comorbidity of aspiraiive pneumonia with chemical, and infection pneumonia, urinary tract and. oropharyngeal infections associated with sepsis on 03 October, 2011. The central catheter and tracheal fluid culture was positive for Pseudomonas aeruginosa (Serratia marecescsns was isolated only in tracheal aspirates) while the urine culture had isolation of raiutiresistant Klebsiella pneumoniae sensitive only to ΙΜΪΡΕΝΕΜ and derivatives. At iCU the sepsis was characterized by hemodynamic changes and crash initially requiring the use of vasoactive drugs and respi.rat.ory support to control the episode. The patient also presented platelet blockade with major bleeding associated
with an acute anemic condition (hemoglobin 8.6 g/dL) also had hypokalemic, hyponatremic and lyraphopenic (lymphocyte count of 3,000/microliter) condition.
Prior conventional treatment
Antibiotic therapy, vasoactive drugs, respiratory support and parenteral nutrition. Treatment with VITER
The immunotherapy treatment, was performed during a single session on 04 October. 201 ] with the informed consent of the patient. VITER immunotherapy was performed as follows:
♦ Application of 0.2 mL of each one of the VITER formulation (Example I). Attenuated yellow fever virus strain 17 D204 20 pg/mL near the main 10 lymphatic territories.
• Application of a low dose of recombinant human mterleukis 2, at a receptor saturation level with a concentration of 1 to 2 million units per meter of body surface.
Result of immunotherapy treatment -with VITER
On 07/ 10/2011, anemia and thrombocytopenia were reversed with a platelet count of
178,000/microliier and a platelet aggregation function compatible with normal parameters. We also noted the normalization of serum electrolytes.
The immunostimu!ation caused immiasocompetence recovery and acti vation of the effector T loop as the lymphocyte count increased from 3,000/microliter on 03 October., 20.1 ito
9,400/microliter on 07/10/201 1. C-reaetive protein concentration was reduced to 61 nag/1 indicating control the infection. It is necessary to mention that the patient
remained imther immunological treatment at "Home care" regimen. On 01/1 1/20.1 1 was diagnosed an aspiration pneumonia confirmed by chest tomography with amazing recovery before the current state of the art in 03 days of immunotherapy associated with antimicrobial treatment according to CT scan of 04/11/201 1 (Figure 2).
Case Conclusion Discharge from hospital to home care on 09/10/20.1 1. The evaluated data and the clinical course of the patient indicate thai the innovati ve immunotherapy was responsible for the amazing recover}' from the critical sepsis condition the patient was in. The continuity
of innntmastirnulaiory treatment also contributes to the improvement of the patient's lite quality and an amazing improvement in life expectancy. According to the state of the art this widespread and terminal cancer condition leads to death in about 1 month., while
the innnimostimulaiiori of the present invention allowed for as unexpected survival of I year and. a half, enjoying the company of relatives.
Example 4: Treating infection (mu!tireststant bacteria of SARS in septic shock)
Patient Information
Patient AMB - female. 39 years old .
Primary Diagnosis
Severe sepsis and Septic shock
Secondary Diagnosis
Presented as cornorbity:
- Severe Acute Respiratory Syndrome (SARS);
-Shock:
- Acute Renal Failure,
- Disseminated Intravascular Coagulation;
- Hepatic failure signs; identification and summary of the clinical history
On 19 Apnl 2007 were hospitalized with dignosis ofcoxnunity pneumonia, non-produced cough and high fever. After 10 hours of hospital admission, patient got worse requiring tranferece to Intense Care Unit (ICU) with respiratory infection and septic shock characterised by:
hipotensiou, SARS; renal and hepatic failure; Disseminated intravascular Coagulation; serum lactate increase, hemodynamic and eletroiytes co!apse. Prior conventional treatment
On 20 April 2007 were treated with Ceftriaxone and Levofioxacin. However, after clinical complication and fCU admission when became essential: i) start respiratory and hemodynamic support; ii) antimicrobial regimen replace by Meropenem with Vancomicin; iii) association of plasma transfusion 08U and JV active protein C to reverse Disseminated Intravascular
Coagulation arid make opsonization, process possible, inspite of all efforts patient did not expcrince any clinical and laboratory improvement.
Proposed IRS with DEC.A treatment associated with conventional treatment
The immunotherapy treatment was performed nine sessions starting on 21/04/201 1 after informed consent of the patient. DECA immunotherapy was performed as follows:
♦ Application of 0.2 mL of each one of the 10 antigenic components (1. Koch's Tuberculin ((lysats inactivated Mycobacterium hovis 0,0036 ng/mL); 2. PPD (0,0036 Mg/mL); 3. Lysate inactivated Staphylococcus (Staphylococcus aureus and Staphylococcus epidermidis in equal parts 6,31 ^ig/mL); 4 Lysate inactivated Streptococcus (Streptococcus pyogenes. Streptococcus pneumonic and Enterococcus faecalis in. equal parts 6,31 itg/mL).; 5. Streptokinase derived from lysate inactivated and purified Streptococcus beta-hemolytic 0,404 ug/mL); 6. Domase derived from lysate inactivated and purified Streptococcus beta-hemolytic 0, 10! pg/mL); 7. Gidiomycm (antigenic extract of Candida albicans 6,31 μg/mL); 8. Trichophytin (antigenic extract of Tricophyton spp 6,31 μ§/ηιΙ,); 9. Lysate inactivated Escherichia co!i (EP.EC 6,31 p.g/m.L); 10. Lysate inactivated Salmonella (Salmonella hongori, Salmonella enterica and Salmonella subierranea in equal parts 6,31 ,ug/mL).
Result of immunotherapy with IRS -DECA associated with conventional treatment
On 26 May 2007 serum eletroiyies and lactate reached normal levels and thrombocytopenia were reversed with a platelet count of 167,000/axnv' and a platelet aggregation function compatible with normal parameters. ON 27.04.2007 SARS still very severe and start to improve. On 29 May 2007 arterial blood gas analysis saturation and p02 were reversed evidencing hemodynamic recover. The immunostimuJation caused immunocompetence recover}.' and activation of the effector T loop with normalized complement, fractions on 28 April 2.007, the lymphocyte count decreased from 21.100/mm3 on 20 April 2007 (that got worse to 43.700/mm3 on 22 April 2007} to 11.000/mm3 on 30 April 2007 when CDS, CD4 and CDS fractions presented proper levels. The respiratory condition improve drastically after 29.04.2007 and respiratory support were removed. Patient was discharged from ICU on 06 May 2007 with complete recover of severe sepsis. On 19 April 2007 was diagnosed an comunity pneumonia contlnned by chest. X-Ray of 24/ April 2007 (Figure 3 - A! ) and worsened to SARS associated with sepsis as can see on CT scan of 27 April 2007 (Figure 3 - B l to B6) with amazing recovery before the current state of the art in 15 days of immunotherapy (6 sessions) associated with antimicrobial treatment according to laboratories and X-Ray (Figure 3 - C I) exams of 06 May 2007.
Case Conclusion
Discharge from hospital on 06 May 2007. The evaluated data and the clinical course of the patient indicate that the innovative immunotherapy was responsible for the amazing recover}' from tire critical severe sepsis and septic shock conditions that the patient was in . Hie continuity of tmmimostimulatory treatment also contributes to the complete extinguish the severe infection and an amazing improvement in life expectancy. According to the state of the art this multiresistant bacteria of SARS in. septic shock associated with renal and hepatic failure conditions leads to death in hours, while the innnunostimulation of the present invention allowed for an unexpected survival with no sequel.
In short, the clinical cases presented hereinabove demonstrate that high complexity illnesses and diseases, with obscure to very poor prognosis, have been addressed, more properly, with advantageous and more efficient approaches through the use of the IRS compositions the present invention.
REFERENCES
In. order to better understand the above concept and definitions related, to the present invention, the following references are incorporated into the present patent application:
1. Pulendran B. The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annual review of immunology. 2015:33:563-606. 2. Steinman RM. Decisions about dendritic ceils: past, present, and fliture. Annual review of immunology. 2012;30: 1-22.
3. Steinman RM, Banchereau I. Taking dendritic cells into medicine. Nature.
2007;449(716]}:419-2ό.
4. Marrin-Fontecfaa A, Baumjohann D, Guarda G, Reboldi A, Hons M, Lanzavecchia A, et ai. CD40L+ CD4+ memory T cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic ceils for T cell priming. The Journal of experimental medicine. 2008;205(l l):2561-?4.
5. Soderberg KA, Payne GW, Sato A, Medzhrtov R, Segal SS, Iwasaki A. Innate control of adaptive immunity via remodeling of lymph node feed arteriole. Proceedings of the National Academy of Sciences of the United States of America. 2005;102{45): 16315-20.
6. Narni-MancineOi E, Campisi L, Bassand D, Cazareth J, Gounon P, Glaichenhaus N, et. al. Memory CD8÷ T cells mediate antibacterial immunity' via CCL3 activation ofTNF/ROI+ phagocytes. The Journal of experimental medicine. 2007;204(9):2075-87.
7. Jeffrey K. Rechallenging immunological memory. Nature medicine. 2007; 13( 10): 1 142.
8. Weisel FJ, Zuccarino-Catania GV, Chifcina M, Slilomchik. Ml. A Temporal Switch in the Germinal Center Determines Differential Output of Memory B and Plasma Cells. Immunity. 2016;44(I): 1 16-30.
9. De Silva NS, Klein. U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 20.15;15(3): 137-48.
10. Saikisto F, Mdaticelli S. The many feces of CD4 T cells; roles in immunity and disease. Seminars in immunology. 2013;25{4):249-51.
i i . Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: ftmctional modules for tailored immunity. European journal of immunology. 2009;39(8):2076-82.
12. Becaitini S, Latorre D, Mele F, Foglierini M, De Gregorio C, Cassotta Ar et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science. 20.15;347(6220):400-6.
13. Zhu J, Paul WE. CD4 T ceils: fates, functions, and faults. Blood. 2008:112(5): 1557-69.
14. Sallusto F, Zie!inski CE, Lanzavecchia A. Human Th 1.7 subsets. European journal of immunology. 2012;42(9):2215-20. 15. Dnhen T. Duhen R, Lanzaveccfaia A. Sailusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypiealiy mirror effector Th cells. Blood. 20 ! 2;i I9( 19):4430-40.
16. Crotty S. Follicular .helper CD4 T cells (TFH). Annual review of immunology.
20 H ;29.621-63.
17. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sailusto F. Dissecting the human immunologic memory for pathogens, Immunological reviews. 2011 ;240< I >; 40-5 Ϊ .
18. Townsend EC, Muxakarai MA, Christodou!ou A, Christie AL, Koster I, DeSouza TA, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase Il-like Trials in Mice. Cancer Cell . 2016;29{4):574-86.
19. fa this issue. Nature Reviews Immunology. 2016: 36{2}:69~.
20. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016; 16(2): 1 12-23.
21. Leavy O. Immune memory: T-box tuning for TRM cell fate. Nat Rev Immunol.
2016;16(2):7I.
22. Mackay LK, Wynne-Jones E. Freestone D, Pellicci DG, Mielke LA, Newman DM. et al. T-box Transcription Factors Combine with the Cytokines TOF-beta and IL-15 to. Immunity. 20i5;43(6): 110M i LID - 10.016/j.immuni.2015.11.008 [doi] LID - S 1074-7613{ 15)00460-4
23. Bird L. Immune memory: ILC2s drive allergen recall Nat Rev Immunol. 20.16: 16(2):72- 3.
24. Halim TY, Hwang ΥΎ, Scanlon ST, Zaghouani R Garbi N, Fallon PG, et al. Group 2 innate lymphoid cells license dendritic ceils to potentiate memory TH2 cell responses. Nat Immunol . 2016 ; 17( I ) : 57-64.
25. Leavy O. Immune memory: Sequential evolution of B cell memory. Nat Rev Immunol. 201.6; 16(2): 72-3.
26. Kugelberg E. immune memory". Lingering human T cells. Nat Rev Immunol.
2016;I 6(2):73.
27. Oliveira G, Ruggiero E, Sianghellini MT, Cieri N, D'Agostino M, Fronzs R et al.
Tracking genetically engineered lymphocytes long-term reveals the dynamics of T. Sci Trans! Med. 2015:?<317):317ral98 LID - 10.1126/scitmnslmed.aac8265 [doij. 28. Mueller SN, Mackay LK. Tissue-resident memory T ceils: local specialists in immune defence. Nat Rev Immunol. 20I6;?6(2):?9>89.
29. Rosenbium MD, Way SS, Abbas AK. Regulatory' T cell memoiy. Nat Rev Immiaiol. 20I6;16(2):90-101.
30. Faster DL. Netea MG, Radbruch A, Rajewsky K, Zinkernagel RM. Immunological memory: lessons from the past and a look to the future. Nat Rev Immunol. 2016, 16(2): 124-8.
31. Laidlaw BJ, Craft JE, Kaecfa SM. The multifaceted role of CD4(+) T ceils in CD8(+) T cell memory. Nat Rev Immunol. 2016; 16(2): 102-11 LID - 10.1038/nri.2015.10 fdoij.
32. Tubo NJ, Fife BT. Pagan AJ, Kotov DI, Goldberg MF, Jenkins MK. Most microbe- specifi c naive CD4(+) T cells produce memoxv cells dunng infection. Science.
2016;35 i (6272):5 i 1-4.
33. Flier! MA, Rittirsch D„ Gao H, Koese! LM, Nadeau B A, Day DE, ei ai . Adverse functions of IL-17A in experimental sepsis. FASE.B journal : official publication of the Federation of American Societies for Experimental Biology. 2008;22(7}:2198~205.
34. Xiao H, Siddiqui J. Remick DG. Mechanisms of mortality in early and late sepsis. Infection and immunity. 2006;?4(9):5227-35.
35. Buras IA, Hoizmann B, Silkovsky M. Animal models of sepsis: setting the stage. Nature reviews Drug discovery. 2005;4{I0):854-65.
36. DiPaolo RJ. Shevach EM. CD4+ T-cell development in a mouse expressing a transgenic TCR derived from a Treg. Eur J Immunol 2009;39(I):234-40.
37. Weber SIL Schewe JC, Lehmann L£, Midler $, Book M. K!aschik S» et ai. Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit Care.
2008;12{5):R128.
38. Schwulst SJ. Muenzer JT, Peck-Palmer OM, Chang KC, Davis CG, McDonough JS, et a!. Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis. Shock.
200S;30(2): 127-34.
39. Martignoni A, Tschop J, Goetzman HS, Choi LG, Reid MD, Johannigman JA, et ai. CD4-expressing ceils are early mediators of the innate immune system dunng sepsis. Shock. 2008:29{5):59i-7.
40. Schmoeckei K, Traffehn S, Eger C, Potschke C, Broker BM. Full activation of CD4+ T ceils early during sepsis requires specific antigen. Shock. 2015:43(2}: 192-200. 41.. Latifi SQ, O'Riordan MA, Levine AD. Interleukin- 10 controls the onset of irreversible septic shock, infection and immunity. 2002;70(8);444 i -6.
42. Querec T, Bennouna S Fau - Alkan S, Alkaa S Fau - Laouar Y, Laouar Y Fau - Gordcn K. Gordea K Fau - Flavell R, Flaveli R Fau - Akira. S, et al. Yellow fever vaccine YF-I7D activates multiple dendritic cell subsets via TLR2. J Exp Med. 2006;203{2):4I3-24.
43. Pulendran B, Miller J, Querec Τϊλ Akondy R, Moseley N, Laur O, et al. Case of yellow fever vaccine— associated viscerotropie disease with prolonged viremia, robust adaptive immune responses., and polymorphisms in CCR5 and RANTES genes. The Journal of infectious diseases. 2008;198(4):500-7.
44. Nakaya Hi. Pulendran B. Vaccinology in the era of high-throughput biology.
Philosophical transactions of the Royal Society of London Series B. Biological sciences.
2015:370(1671).
45. Hagan T, Nakaya HI, Subramaniam S. Pulendraa B. Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine. 20.15.
46. Li S, Nakaya HI, Kazrain DA, Oh JZ, Pulendran 8. Systems biological approaches to measure and understand vaccine immunity in humans. Seminars in immunology.
2013;25(3):209-I 8.
47. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nature
immunology . 2011.12(6): 509-17.
48. Buonaguro L, Pulendran B. Immunogenomics and systems biology of vaccines.
Immunological reviews. 201 l ;239( i): 197-208.
49. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010;33(4):5 16-29.
50. Ahmed R, Pulendran B. Learning vaccinology from viral infections. The Journal of experimental medicine. 2011;208{12):2347-9.
51 . Edward F. McCarthy MD. THE TOXINS OF WILLIAM B. COLEY AND THE TREATMENT OF BONE AND SOFT-TISSUE SARCOMAS. '.Hie Iowa Orthopaedic Journal. 200626.
52. Waldner H. Activation, of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. Journal of Clinical. Investigation. 2004;! 13(7): 990- 7. .53. Maryanski JL, Boon T. immunogenic variants obtained by mutagenesis of mouse mastocytoma FS 15. IV . Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. European journal of immunology. 1982; i2(S):406-]2.
54. Boon T, Maryanski J. Tumour ceil variants with increased immnnogeniciiy obtained by mutagen treatment. Cancer Surv. 1985 ;4(I): 135-48.
55. Koguchi Y, Thaaiand TJ, Slifka MK, Parker DC. Preformed CD40 Ugand exists in secretory lysosomes in. effector and memory CD4+ T ceils and is quickly expressed on the ceil surface in an antigen-specific manner. Stood. 2007; i i0(?):2520~7.
56. Nami-Maacinelli E, Soudja SM, Crozat K, Dalod M, Gounon ?, Geissmann F, et al . Inflammatory monocytes and neutrophils are licensed to kill during memory responses in vivo. PLoS pathogens. 201 J ;7(12):el002457.
57. Marai-Mancinelli E, Vivier E. Delivering three punches to knockout, intracellular bacteria. Cell. 2014;I57(6): 1251-2.
58. Bajenoff M, Nami-Mancineili E, Brau F, Lauvau G. Visualizing early splenic memory CDS+ T cells reactivation against, intracellular bacteria, in the mouse. PloS one.
201.0;5(7):el l524.
59. Sondja SM. Ruiz AL, Marie JC, Lauvau G. Jafiammaiory monocytes activate memo.ry CD8(÷) T and innate NK h-mphocytes independent of cognate antigen during microbial pathogen invasion. Immunity. 2012 ; 37(3 }: 549-62.
60. Kohihapp FL Kaufman HI... Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22(5): 1048-54.
61 . Topalian SL, Woichok JD, Chan TA, Me!lman L Palucka K, Banchereau J, et al.
immunotherapy: The path to win the war on cancer? Ceil . 2015; 161(2): 185-6.
62. Kaufman HL. Vaccines for melanoma and renal cell carcinoma. Seminars in oncology. 2012;39{3}:263-75.
63. GHmcher Hi LindvaH O, Aguirre V, Topalian SL, Musunuru K, Fauci AS. Translating research into therapies. Cell. 2012;i48(6): 1077-8,
64. Makaya HI, Wramrnert J. Lee EK, Racioppi L, Marie-Kunze S; Hainiag WN, et al. Systems biology of vaccination for seasonal influenza in humans. Nature immunology.
201 1 ; i 2(8}:786-9.5. 65. Sallusto F, Lanzaveccbia A, Araki K, Ahmed R. From vaccines to memory and. back. Immunity . 2010; 33(4):451 -63.
66. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D. ei al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology. 2009; 10(1 ): 1 16-25.
67. Axnanna IJ, Carlson NE. Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. The New England journal of medicine. 2007;357(19): 1903-15.
68. Querec T, Bennouna S, AJkan S, Laouar Y, Gorden K, Fiavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to simulate polyvalent immunity. The Journal of experimental medicine. 2006;203{2):413~24.
69. Pulendran B, Ahmed R. Translating innate immunity into immunological memory : implications tor vaccine development. Cell. 2006;124(4):849-63.
70. Araanrsa IJ. Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunological reviews. 2006:211:320-37.
71. Arlen PM, Kaufman HL, DiPao!a RS. Pox viral vaccine approaches. Seminars in oncology. 2005;32(6):549-55.
72. Hammarlund E, Lewis MW, Hansen SG, Stre!ow L.l Nelson J A, Sexton GL et al .
Duration of antiviral immunity after smallpox vaccination. Nature medicine. 2003;9{9): 1 .131-7.
73. Crotty S, Feigner P. Davies H. Giideweil J, Villarreal L, Ahmed R. Cutting edge: long- term B ceil memory in humans after smallpox vaccination. Journal of immunology.
2003:17 l(I0):4969-73.
74. Cono J, Casey CCx Bell DM, Centers for Disease C, Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep. 2003:52(KR-4): l-28.
75. Frey SB, Couch RB. Tacket CO, Treanor J J, Wolff M, Newman FK. et al. Clinical responses to undiluted and diluted smallpox vaccine. The New England journal of medicine. 2002:346(17):.! 265-74.
76. Ahmed R. Gray D. immunological memory and protective immuniiy; understanding their relation. Science. !.996;272{525S):54-60.
77. Koplan JP, Matton KJ. Smallpox vaccination revisited. Some observations on the biology of vaccinia. The American journal of tropical medicine and hygiene. i975;24(4):656~ 63. 78. Theiler M, Smith HH. 1¾e Use of Yellow Fever Virus Modified by in Vitro Cultivation for Human Lran ionization. The Journal of experimental medicine. 1937;65(6):787-800.

Claims

WHAT IS CLAIMED
1. A pharmaceutical product comprising one or more antibiotics and one or more IRS immunogenic compositions for mod.ulaiing the immune system comprising a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or fractions and combination thereof comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (D AMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with helminths, and (F) antigenic agents with molecular patterns associated with prions: and one. or more physiologically acceptable carriers, excipients, diluents or solvents.
2. The pharmaceutical product of claim 1 wherein the antibiotics are selected from the following classes: Amino Acid Derivatives, Aminoglycosides, Auxeolic Acids, Aziridines, Ansamycins, Benzenoids, Benztmidazoles, Carbapenems, Cephalosporin, Coumarin-glycosides, Diphenyl Ether Derivatives. Epipolythicxiioxopiperazines, Fatty Acid Derivatives,
Glucosamine. Glycopepfcides, Imidazoles, indol Derivatives, Lipopeptides Macroiactams, Macroitdes, Nucleosides. Penicillins and Cephalosporins (beta-Lactams), Peptides, Peptidyl Nucleosides, Phenicoles, Polyenes, Polyethers, Pyridines and Pyrimidines, Quinolones and Fluoroquinolones, Statins, Steroids, Sulfonamides, Taxoides and Tetracyclines.
3. The pharmaceutical product of claim 2 wherein the antibiotics are selected from the following classes: ausarr.ycins. Penicillins, Cephalosporins, Carbapenems and Lipopeptides.
4. The pharmaceutical product of claim 1 wherein the antigenic agents are. selected from at least four groups (A), <B), (C), (D), (E) and (F).
5. The pharmaceutical product of claim 1 comprising from 4 to 20 antigenic agents selected from the group consisting of antigenic agents derived from: domase, levedurin, oidiomycin, purified protein derivative of Koch's bacillus (PPD), prions, streptokinases.
Streptococcus toxoid diphtheria toxoid, tetanus toxoid, Koch '$ original, tuberculin, inactivated Ascaris lumbricoides fysates, Aspergillus spp., Aspergillus fiavus, Aspergillus fumigatus.
Aspergillus terreus, Candida albicans, Candida glabrata, Candida parapsilosis. Chlamydia spp., Chlamydia pneumoniae, Chlamydia psitxaci. Chlamydia trachomatis, Cryptosporidium spp. . Dermatophytes, Entamoeba hystolihca, Enterobhts verrmcularis, Enterococcus faecalis, Epidermophyton fioocosum, Escherichia cob, Giardia kmiblia, Haemophilus influenzae, Microsporum cards, Mycobacterium spp. , Mycobacterium bovis, Mycobacterium leprae, Mycobacterium tubercndosis, Neisseria gonorrhoeae. Human papillomavirus, Polio virus, Proteus spp., Proteus mirabilis. Proteus penerii, Proteus vulgaris, Salmonella spp. . Salmonella bongori. Salmonella enterica, Serratia spp., Serratia liguefaciens, Serratia marcencens.
Shigella spp., Shigella flexneri. Shigella sonnei. Staphylococcus spp.. Staphylococcus aureus, Staphylococcus epidermidis, Strongyloides siercoralis, Streptococcus spp.. Streptococcus bovis. Streptococcus viridans. Streptococcus equinus, Streptococcus pneumoniae, Streptococcus pyogenes, Toxoplasma gondii, Trichomonas vaginalis, trichophyttn, Trichophyton spp..
Trichophyton rubrum. Trichophyton tonsurans, Trichophyton mentagrophytes, yellow fever virus, hepatitis B vims, rubella virus, varicella zoster virus, variola virus, mumps virus, measles virus, .herpetic virus and vaccinia virus or synthetic analogues present pathogen-associated molecular patterns (PAMPS) and / or danger-associated molecular patterns (DAMPS) associated wife these antigenic agents.
6. A method to treat sepsis and raulti resistant bacterial infection is a human or an animal comprising adirunistering to the human or animal an effective amount of one or more antibiotics and one or more IRS immunogenic compositions comprising a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or fractions arid combinations thereof, comprising pathogen-associated molecular patterns {PAMPS} and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (8) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with helminthes, and (F) antigenic agents with molecular patterns associated with prions; and one or more
physiologically acceptable carriers, excipients, diluents or solvents.
7. A method, to modulate so immune system response m a human or an animal who has a bacterial infection comprising administering to the human or animal an effective amount of one or more IRS immunogenic compositions comprising a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (D AMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses. (C) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents wife molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with, fcelmrathes, and (F) antigenic agents with molecular patterns associated with prions; and one or more physiologically acceptable carriers, excipients, diluents or solvents.
PCT/BR2018/000004 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject Ceased WO2018145180A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL268626A IL268626B2 (en) 2017-02-13 2018-02-15 Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient
KR1020197026857A KR20190139209A (en) 2017-02-13 2018-02-15 Immunogenic Compositions for Modulating the Immune System and Methods of Treating Bacterial Infections in Individuals
JP2019564565A JP2020507629A (en) 2017-02-13 2018-02-15 Immunogenic compositions for modulating the immune system and methods for treating a bacterial infection in a subject
MX2019009689A MX2019009689A (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject.
CN201880023729.7A CN110709099B (en) 2017-02-13 2018-02-15 Immunogenic compositions for modulating the immune system and methods of treating bacterial infections in subjects
AU2018217441A AU2018217441B2 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
EP18751350.2A EP3579868A4 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
RU2019128674A RU2019128674A (en) 2017-02-13 2018-02-15 IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS IN SUBJECT
BR112019016670A BR112019016670A2 (en) 2017-02-13 2018-02-15 immunogenic composition to modulate the immune system and methods to treat bacterial infections in an individual

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/431,329 US10213504B2 (en) 2011-03-18 2017-02-13 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
US15/431,329 2017-02-13

Publications (1)

Publication Number Publication Date
WO2018145180A1 true WO2018145180A1 (en) 2018-08-16

Family

ID=63106848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2018/000004 Ceased WO2018145180A1 (en) 2017-02-13 2018-02-15 Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject

Country Status (10)

Country Link
EP (1) EP3579868A4 (en)
JP (1) JP2020507629A (en)
KR (1) KR20190139209A (en)
CN (1) CN110709099B (en)
AU (1) AU2018217441B2 (en)
BR (1) BR112019016670A2 (en)
IL (1) IL268626B2 (en)
MX (1) MX2019009689A (en)
RU (1) RU2019128674A (en)
WO (1) WO2018145180A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096270A1 (en) * 2003-04-30 2004-11-11 Medi Service S.R.L. Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
WO2005077408A2 (en) * 2004-02-06 2005-08-25 Vaxinnate Corporation Compositions of pamps and listeria monocytogenes and methods of use
WO2008020330A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2008080628A1 (en) * 2006-12-29 2008-07-10 Pevion Biotech Ag Non-specific immunostimulating agents
WO2010003009A2 (en) * 2008-07-01 2010-01-07 Emory University Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
WO2011004263A2 (en) * 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
WO2012122618A1 (en) * 2011-03-17 2012-09-20 Nowill Alexandre Eduardo Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response
US20150110830A1 (en) * 2009-07-16 2015-04-23 Novartis Ag Detoxified escherichia coli immunogens
US20150238589A1 (en) * 2010-07-26 2015-08-27 Qu Biologics Personalized Site-Specific Immunomodulation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096270A1 (en) * 2003-04-30 2004-11-11 Medi Service S.R.L. Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
WO2005077408A2 (en) * 2004-02-06 2005-08-25 Vaxinnate Corporation Compositions of pamps and listeria monocytogenes and methods of use
WO2008020330A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2008080628A1 (en) * 2006-12-29 2008-07-10 Pevion Biotech Ag Non-specific immunostimulating agents
WO2010003009A2 (en) * 2008-07-01 2010-01-07 Emory University Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
WO2011004263A2 (en) * 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
US20150110830A1 (en) * 2009-07-16 2015-04-23 Novartis Ag Detoxified escherichia coli immunogens
US20150238589A1 (en) * 2010-07-26 2015-08-27 Qu Biologics Personalized Site-Specific Immunomodulation
WO2012122618A1 (en) * 2011-03-17 2012-09-20 Nowill Alexandre Eduardo Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRUZ, F. ET AL.: "Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative", EUROPEAN UROLOGY SUPPLEMENTS, vol. 8, no. 9, 2009, pages 762 - 768, XP026502055, Retrieved from the Internet <URL:https://doi.org/10.1016/j.eursup.2009.07.002> *
ROZY, A. ET AL.: "J. Bacterial immunostimulants - mechanism of action and clinical application in respiratory diseases", PNEUMONOL ALERGOL POL., vol. 76, no. 5, 2008, pages 353 - 359, XP002728608 *
See also references of EP3579868A4 *

Also Published As

Publication number Publication date
RU2019128674A3 (en) 2021-06-18
IL268626B2 (en) 2024-04-01
EP3579868A1 (en) 2019-12-18
AU2018217441B2 (en) 2024-11-07
JP2020507629A (en) 2020-03-12
CN110709099A (en) 2020-01-17
MX2019009689A (en) 2019-12-18
RU2019128674A (en) 2021-03-16
IL268626A (en) 2019-10-31
EP3579868A4 (en) 2021-01-06
CN110709099B (en) 2024-03-29
BR112019016670A2 (en) 2020-04-14
KR20190139209A (en) 2019-12-17
AU2018217441A1 (en) 2019-10-03
IL268626B1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CN103717233B (en) Immune composition for modulating the immune system and uses thereof, methods for treating and preventing diseases, methods for inducing cell regeneration and methods for renewing the immune response
KR101656252B1 (en) Immunopotentiating composition and process for producing same
US7521040B2 (en) Immunotherapy for humans
US8425913B2 (en) Immunogenic agents against Burkholderia pseudomallei and/or Burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from Burkholderia pseudomallei
US10213504B2 (en) Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
WO2018145180A1 (en) Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
KR20200065257A (en) Vaccine composition for prevention or treatment of tuberculosis containing Rv3463 protein
TW201919661A (en) Method for inducing an M1 dominated immune response and pharmaceutical compositions
NZ616823B2 (en) Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18751350

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019564565

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019016670

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197026857

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018751350

Country of ref document: EP

Effective date: 20190913

ENP Entry into the national phase

Ref document number: 2018217441

Country of ref document: AU

Date of ref document: 20180215

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112019016670

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190812